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 ABSTRACT 
 
 Acute Lymphoblastic Leukemia (ALL) is the most common malignancy of 
childhood, constituting 31 percent of all childhood malignancies.   Treatment 
strategies to target ALL include chemotherapeutic agents, irradiation of the neck 
and/or spine, and bone marrow transplantation.   The aggressive nature of anti-
neoplastic therapies often produces numerous craniofacial and dental sequelae 
as well as additional harmful effects to the entire body.  Cranial irradiation may 
adversely affect the hypothalamic-pituitary axis decreasing growth hormone 
production.  Consequently, children with ALL may experience a transient or 
permanent reduction in growth iatrogenically.  Hand-wrist radiographs are 
valuable for evaluating maturational status in children with ALL.  These 
radiographs allow for the comparison of a child’s chronological age with relative 
“bone age.”  OBJECTIVE:   This study used hand-wrist radiographs to determine 
the maturational status of children treated with ALL.  Bone age was compared to 
the child’s chronological age to determine the delayed, normal, or advanced 
tempo of growth.  The null hypothesis was that anti-neoplastic therapies have no 
discernible effect on a child’s tempo of bone maturation.  METHODS:  Hand-
wrist radiographs (n=108 films) of 73 children (39 boys, 34 girls) treated at St. 
Jude Children’s Research Hospital for ALL were evaluated to assess “bone age.”  
Mean chronological age at diagnosis was 4.54 years (sd = 2.81).  The number of 
 films per child was highly skewed, since most were taken soon after the 
diagnosis of ALL (and, thus, close to the onset of treatment).  Bone ages were 
scored for each of the 73 patients based on Greulich and Pyle’s 1959 standards 
(GP2), specifically the atlas method.    RESULTS:  We supposed that the 
combination of antimitotic drugs used to treat ALL would discernibly depress 
the childrens’ tempos of growth, so that BA-CA (bone age-chronological age) 
would become negative (and become larger during the course of treatment).  We 
found no evidence of this in our study.  In fact, since there was no depression of 
the rate of maturation during treatment, there was no need for a compensatory, 
or “catch-up,” phase.  There was, then, no evidence that treatment for ALL had 
any effect on the progress of hand-wrist bone age towards maturity.  There also 
was no detectable effect on the tempo of growth for those treated with cranial 
irradiation versus children with chemotherapy alone.  In conclusion, treatment 
for ALL spares the tempo of growth as measured by HW bone age.  This is a 
favorable outcome since treatment did not alter the duration of growth, so 
prognosis of normal adult status is good.  This finding accounts for several prior 
studies that reported normal adult body dimensions (in the absence of radiation 
treatment) in subjects treated for ALL in childhood. 
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 CHAPTER I 
 
INTRODUCTION 
 
 Acute Lymphoblastic Leukemia (ALL) constitutes 31 percent of all 
childhood malignancies and now represents the most common malignancy of 
childhood.  ALL strikes children primarily between two and ten years of age.  
However, it may also attack adolescents and adults.  Higher rates of ALL have 
been found among populations in North America, Northern and Western 
Europe, and Oceania, whereas lower rates have been seen in Asian and African 
populations.  Though the cause of ALL is not known, several substances or 
entities have been implicated to include:  ionizing radiation, the used of drugs 
and chemicals, as well as various viruses. 
 As cure rates for children with ALL approach 80 percent, this sample 
provides an excellent means by which to examine anti-neoplastic treatment 
influences on growth and development.  Chemotherapy and radiation (of the 
head and neck, as well as the spine) are commonly utilized in the treatment of 
ALL. 
 As radiation and chemotherapeutic agents often fail to differentiate 
between metabolically active normal cells and neoplastic cells, a patient’s overall 
tempo of growth is often adversely affected.  Growth and development describe 
 the changes an individual progresses through from conception until death.  
Growth is defined as a change in physical size of the organism as a whole or any 
of its parts.  Development is defined as a change in proportion and/or an 
increase in complexity.  Development indicates not only a change in shape of the 
entire body, but also individual anatomical structures. 
 Sonis et al. (1990) noted that an altered hypothalamic-pituitary function 
may result in decreased growth hormone production.  Hypopituitarism has been 
shown to follow high-dose irradiation of both intra- or extracranial tumors (Tan 
and Kunaratnam 1966; Shalet et al. 1975; Richards et al. 1976).  Several studies 
related the prevalence of diminished stature in children with ALL.  However, 
these studies failed to demonstrate a decrease in the overall tempo of growth.  
Kirk et al. (1987) reported high rates of only diminished stature in children 
treated for ALL, however overall growth retardation was not demonstrated.  
Conversely, Clayton et al. (1998) concluded that while chemotherapy did 
contribute significantly to diminished stature in children with ALL, mean loss in 
the majority of children was not high enough to substantiate GH replacement 
therapy.   
 Bones in the skeleton may be analyzed throughout an individual’s life—
from birth, through skeletal maturation, finalized with the end of life (Greulich 
and Pyle 1959).  Chronological age, or a person’s age in calendar years, serves as 
the standard by which most laypersons gauge maturity.  However, this 
 measurement often does not adequately reflect a person’s biological maturity or 
development, particularly when considering those periods of infancy or 
childhood.  The framework or connective tissues of the body serve as a standard 
applicable to general body development.  Skeletal or biological age, also termed 
“developmental age” and “physiological age,” reflects the level of maturity 
achieved by the individual (Todd 1937).  Average bone or skeletal ages, then, 
illustrate the maturation status in which normal children, male and female, 
match up with their corresponding calendar or chronological age (Jimenez-
Castellanos et al. 1996). 
 Hand-wrist radiographs are commonly used in the assessment of 
biological age because the hand and wrist are reasonably accessible and those 
vital organs particularly at risk to radiation damage are not in close proximity.  
A hand-wrist bone age serves as the measure by which a child’s chronological 
age may be compared.  The child’s developmental status may be shown as 
delayed, normal, or advanced.  Hand-wrist radiographs serve as an excellent 
measure to determine the effects of anti-neoplastic therapy. 
 The present study analyzed the hand-wrist radiographs of 73 children 
treated at St. Jude Children’s Research Hospital in Memphis, Tennessee for ALL.  
The number of films per child was highly skewed, ranging from one to four per 
child.  The focus of bone age analysis centered on determining whether the 
 tempo of growth was retarded based on treatment with chemotherapy and/or 
radiation.   
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER II 
 
          REVIEW OF THE LITERATURE 
 
Introduction 
Acute Lymphocytic Leukemia (ALL)—also known as Acute Lymphatic, 
Acute Lymphoblastic, or Acute Lymphogenous Leukemia—now represents the 
most common malignancy of childhood, constituting 31 percent of all childhood 
malignancies (Niemeyer and Sallan 1998; Berg et al. 2000).  Figure 1 is a barchart 
of the most common types of cancer in children under 15 years of age, with their 
percentage of total cases (Mirro 2000).  While ALL accounts for nearly 75 percent 
of all leukemias in children, it accounts for less than one percent of all adult 
malignancies (Perkins et al. 1997; Berg et al. 2000).   
 The earliest descriptions of leukemia in the clinical setting were made 
independently by Bennett in Scotland and Virchow in Germany; each published 
his discovery in 1845.  Their observations were based on a number of autopsies 
of patients with “enlarged spleens and purulent-appearing blood” in which 
microscopic analysis revealed a marked increase of “colorless corpuscles.”  
Bennett suggested that the etiology of the increased white blood cell counts was 
due to inflammation, while Virchow preferred the term “weisses Blut,” or white 
blood, that was later rephrased in Greek as “leukemia” (Perkins et al. 1997).  The 
foremost breakthrough in cellular identification of the leukemias took place in 
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Fig. 1. Classes of cancer in children under 15 years of age,
expressed as the pecentage of total cases.
Source: Mirro J. Treatment options. In Steen RG and Mirro J.
Childhood cancer.  Cambridge:  Perseus Publishing, 2000, p 11-7.
 1891, when Paul Ehrlich established differential methods of staining and further 
categorized neutrophilic, eosinophilic, and basophilic granulocytes (Bennett 
1990).     
ALL strikes children primarily between two and ten years of age, with the 
peak age between two and three years.  However, it can also attack adolescents 
and adults, with a substantial increase around 65 years of age (Berg et al. 2000).  
Figure 2 depicts overall incidence statistics by race and sex (Pui 1999).  A survey 
by the Surveillance, Epidemiology, and End Results Program (SEER) showed 
that the incidence of ALL in the United States increased from 2.7 to 3.3 cases per 
100,000 children aged 0 to 14 years old during the years 1973 to 1995.  Latinos 
represent the highest rates of ALL for both boys and girls in the United States 
(Pui 1999).  Each year, around 2,000 to 2,500 new cases of ALL are diagnosed in 
the United States (Niemeyer and Sallan 1998).   
Significant geographic differences exist with regard to the incidence of 
ALL.  Higher rates of ALL have been found among populations in North 
America, Northern and Western Europe, and Oceania, whereas lower rates have 
been seen in Asian and African populations.  The highest rates of ALL in 
European males have been reported for Spain, whereas the highest rates for 
European females have been reported for Denmark (Pui 1999).   
The cause of ALL is not known, though several explanations for an 
overall cause of leukemia have been explored.  Numerous environmental factors  
Fig. 2. Age-specific incidences for ALL by race and sex.
Source: Pui CH. Acute lymphoblastic leukemia.  In Lee GR.
Wintrobe’s clinical hematology.  Baltimore: Williams & Wilkins,
1999, p 1141-53.
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 have been examined, including ionizing radiation, the use of drugs and 
chemicals, as well as various viruses.  The incidence of leukemia was shown to 
be elevated in persons exposed to nuclear weapons in Hiroshima and Nagasaki, 
thus confirming the association between ionizing radiation and leukemia.   
Several chemical substances, such as benzene, chloramphenicol, and 
phenylbutazone, have also been linked to the disease.  Additionally, several 
debilitating viruses have shown associations with leukemia.  These include a 
statistical linkage of the Epstein-Barr virus with African Burkitt’s lymphoma, the 
human T-cell leukemia-lymphoma virus I (HTLV-I) with adult T-cell leukemia-
lymphoma (ATL), and the HTLV-II virus with atypical hairy-cell leukemia 
(Perkins et al. 1997). 
 
The Composition of Blood 
ALL primarily targets lymphocytes in the bloodstream.  A vital organ that 
delivers hemoglobin, oxygen, and other essential nutrients,  blood also 
transports chemicals and hormones to various cells throughout the body.  Blood 
is comprised of a variety of proteins that aid in nutrition, bodily defense, and 
hormonal regulation.  Whole blood is composed primarily of three elements in a 
clear protein-rich medium known as serum or plasma:  red blood cells, platelets, 
and white blood cells.  Red blood cells represent roughly 45 percent of whole 
blood, with plasma contributing an additional 55 percent, and white blood cells 
 and platelets making up slightly below one percent (Ball and Lelek 2003).  
Hematopoiesis, the process of blood cell formation and development, is 
distinguished by a steady turnover of cells and is carried out by stem cells in the 
bone marrow (e.g., Bell and Hughes 1997).  Bone marrow is a sponge-like, fatty 
material found within the confines of most bones.  Red bone marrow, the 
marrow responsible for the production of blood cells, is found predominantly in 
the pelvis, sternum, ribs, skull and vertebral bodies in adults—and more broadly 
in children (e.g., Ball and Lelek 2003).   
Blood cells are derived from pluripotent stem cells found in bone 
marrow, and they possess the ability to differentiate into a single cell lineage.  
Figure 3 delineates this stem cell hierarchy.  The clinical manifestations of 
leukemia would be expected to reflect the level at which the malignant 
transformation took place (Mauer 1990). 
 Red blood cells, or erthyrocytes, have an average life span of 120days.  
Morphologically, these cells are biconcave discs without nuclei. These cells 
contain hemoglobin, an iron-rich protein that transports oxygen from the lungs to 
tissues and organs throughout the body.  The blood is also responsible for 
carbon dioxide transport and elimination.   A deficiency of red blood cells, 
known as anemia, can result in fatigue and weakness, nausea, as well as an 
increased temperature and pale discoloration of the skin.  Anemia may be 
induced by a number of biological events, including nutritional deficiency,  
Fig. 3. A scheme for blood cell derivation, differentiation, and
proliferation.
Source: Mauer AM. Clinical features of human leukemia. Baltimore:
Johns Hopkins University Press, 1990, p 1-7.
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 hemorrhage, increased hemolysis, bone marrow transplants, infection, heredity 
or an acquired deficit (e.g., Bell and Hughes 1997). 
Platelets, which are proteins essential to the blood clotting process, are 
also formed in the marrow and are descendents of megakaryocytes.  These cells 
have an approximate life span of 5 to 10 days.  A deficiency of platelets can 
result in spontaneous bleeding with blood loss into tissues and organs of the 
body.  Excessive bruising of the skin often is seen with platelet deficiencies (Ball 
and Lelek 2003). 
White blood cells, or leukocytes, are involved primarily in the host  
defense against disease-producing bacteria and parasites.  The three main types 
of leukocytes―monocytes, granulocytes, and lymphocytes―fulfill separate and 
unique roles in the defense process.  Monocytes are highly efficient and effective 
at recognizing and digesting foreign bodies (or antigens), and may also aid in 
long-term defense through antigen presentation to T-lymphocytes.  The fully 
differentiated monocyte is referred to as a macrophage (e.g., Ball and Lelek 2003).   
Granulocytes comprise neutrophils, basophils, and eosinophils.  
Neutrophils constitute the vast majority of the granulocyte population and are 
skilled at identifying and destroying bacteria and other harmful substances.  As 
neutrophils are crucial in the defense against bacterial and fungal infections, 
suppression or absence of these cells leaves the body open to injury from 
viruses, bacteria, or other harmful parasites.  Basophils are responsible for the 
 release of histamine during inflammation, while eosinophils target parasites and 
aid in the ingestion of an antigen-antibody compound (e.g., Ball and Lelek 2003).  
Lymphocytes defend the lymphatic system and blood.  The lymphatic 
system is an extensive network of vessels interconnected with small masses of 
lymphatic tissue termed lymph nodes.  Lymph nodes lie along the network of 
lymphatic vessels and cluster primarily in the pelvis, neck, abdomen, and 
underarm.  The spleen, which is located in the upper abdomen, the thymus, 
which lies beneath the sternum, and the tonsils and adenoids, which reside in 
the posterior throat, are also components of the lymphatic system.  Tissue fluid 
carried throughout the lymphatic system, or lymph, is typically clear and watery 
in appearance, with the same consistency of blood plasma.  The main functions 
of the lymphatic system are:  absorption and transport of fat from the intestine to 
the venous system; formation of a defense mechanism for the entire body; and 
drainage of tissue fluid; as well as collection and transport of lymph from the 
tissue spaces to the venous system (Moore and Dalley 1999). 
Lymphocytes are the second most numerous cells in the blood, 
comprising 20 to 44 percent of adult blood cells.   Lymphocytes develop from 
multipotent hematopoietic stem cells that possess the means to mature into a 
range of different kinds of blood cells.  These stem cells develop in the bone 
marrow and then differentiate into fully functional white blood cells.   The 
common lymphoid progenitor cell may progress into T lymphocytes (T cells) or 
 B lymphocytes (B cells).  T cells mature in the thymus, while B cells develop in 
the bone marrow (e.g., Bell and Hughes 1997). 
Lymphocytes attack infection primarily through the production of 
antibodies, which fight germs and other harmful bacteria present with an 
infection.  Upon presentation of specific antigenic stimuli, lymphocytes may 
transform into immunologically competent cells.  This transformation is marked 
by an increase in size, due to an increase in RNA in the cytoplasm or DNA in the 
nucleus (e.g., Bell and Hughes 1997). 
Cancer most commonly involves anaplasia, or the loss of a normal pattern 
of the growth of cells.  Anaplasia is characterized by an increased variability in 
the appearance of cells.   Anaplastic growth is common to nearly all tumors, 
benign or malignant.  Furthermore, the degree of anaplasia may be important 
establishing prognosis of a tumor (Steen 2000). 
The exact cause of leukemia, while currently deemed idiopathic, may 
arise from certain genetic events occurring at particular stages of stem cell 
development.  The type of leukemia may then be linked to the genetic event and 
stem cell from which the flaw derived (e.g., Ball and Lelek 2003).   
 
Four Major Types of Leukemia 
 Four major forms of leukemia are recognized:  acute lymphocytic, acute 
myelogenous, chronic lymphocytic, and chronic myelogenous.  The term “acute” 
 refers to leukemias that have a rapid onset and are characterized by an increased 
number of young cells.  In contrast, the term “chronic” denotes a slower 
progressing disease, involving more developed cancer cells.  Acute leukemias 
are most often fatal, while chronic leukemias follow longer courses of 
development.  Lymphocytic leukemia involves cells of lymphoid origin, while 
myelogenous leukemia involves cells of myeloid origin (Ball and Lelek 2003).  A 
classification of leukemia subtypes is listed below (Mauer 1990). 
  I. Acute 
  A.  Lymphocytic 
  B.  Nonlymphocytic 
  II. Chronic 
A. Lymphocytic 
B. Myeloproliferative disorders  
1. Chronic myelocytic leukemia 
2. Polycythemia rubra vera 
3. Essential thrombocythemia 
III. Myelodisplastic syndromes 
IV. Miscellaneous chronic leukemias 
A. Hairy cell leukoplakia 
B. Adult T-cell leukemia 
C. Sézary syndrome 
D.  Tγ-cell leukemia   
  
 ALL may be separated into three groups dependently on the apparent 
size of the constituent lymphoblasts.  L1 lymphoblasts are relatively small and 
exhibit uniform structure and size among abnormal lymphoblasts.  L2 
lymphoblasts are larger in size and exhibit more structural and size variation, 
termed “structural heterogeneity.”  L3 lymphoblasts are the largest in size and 
contain large voids, termed vacuoles.  The L3 subtype, referred to as “Burkitt’s 
 type” because of its morphological similiarities to Burkitt’s lymphoma, carries 
the worst prognosis of all subtypes (Perkins et al. 1997).   
The L1 subtype is prevalent in childhood ALL, occurring in roughly 85 
percent of all cases.  The L2 subtype is most common in older people, while the 
L3 subtype represents only 1 to 2 percent of all ALL cases.  These three subtypes 
may be further divided based on relative B or T cell similarities, demonstrated 
through a process called phenotyping.  B lymphocyte lineage subtypes, which 
account for approximately 85 percent of ALL cases, are noticed by isolating cell  
surface markers on the leukemic blasts that match those of normal B 
lymphocytes.  T lymphocyte lineage subtypes, which account for approximately 
15 percent of ALL cases, are noticed by isolating cell surface markers on the 
leukemic blasts that match those of normal T lymphocytes.   Detailed analysis of 
an ALL case often identifies surface antigenic or molecular markers that may aid 
in identification or classification of the specific disease type (Berg et al. 2000). 
 
Acute Lymphoblastic Leukemia 
 
Symptoms 
Patients with ALL usually present with symptoms coincident with bone 
marrow invasion and deterioration (Perkins et al. 1997).  Most often, this spread 
of leukemic cells is uncontrolled and extramedullary.  The most common sites of 
 extramedullary ALL involvement are the central nervous system, lymph nodes, 
testes, liver, kidney and spleen.  The central nervous system (CNS) and the testes 
often carry the highest clinical implications (Berg et al. 2000).  Inherent anemia, 
thrombocytopenia, and neutropenia, or the depletion of red blood cells, platelets, 
and white blood cells, respectively, often manifest in signs of weakness and 
debility.  Bleeding problems often range from mild complications such as 
petechiae, bruising, and mucosal bleeding, to severe problems such as GI 
bleeding and CNS hemorrhage.  Hepato-splenomegaly and lymphadenopathy 
may also be noticed and attributed to lymphoblast engorgement (Perkins et al. 
1997).  Oral manifestations of ALL include swollen and bleeding gums, as well 
as relative periodontal infections (Greene 2002).  Approximately 40 percent of 
childhood leukemia patients exhibit bone and joint manifestations, such as pain 
or sensitivity.  Numerous patients, as high as 25 percent, can present with 
fractures or osteopenia most commonly of the long bones.  These changes or 
symptoms are usually seen in areas of accelerated growth and development, 
such as the knees, wrist, and ankles.  Niemeyer and Sallan (1998:1255) stated 
these symptoms, “may be the result of direct leukemic infiltration of the 
periosteum, periosteal elevation of underlying cortical disease, bone infarction, 
or expansion of the marrow cavity by the leukemic cells.”  Overall signs and 
symptoms depend on a range of factors including age of onset, duration of 
treatment, and subtype of ALL. 
  
Prognosis 
 “Progress in the treatment of ALL has been incremental, beginning with 
the development of effective therapy for CNS disease, followed by 
intensification of early treatment” (Pui 1999:1141).  Cure rates for children 
currently are near 80 percent, while rates for adults approximate 30 to 40 
percent.  These high cure rates demonstrate the obvious progress that has been 
made in the treatment of ALL (Pui 1999). 
 
Treatment Strategies 
The current high and improving survival rates of ALL and other forms of 
cancer are due in large part to research efforts and improved treatment strategies 
(Goho 1993).  When considering the treatment course for a person with ALL, 
physicians examine a number of factors:  the ALL subtype, the composition of 
previous treatments and its successes or failures, levels of leukemic cells in the 
blood, the presence or absence of chromosomal aberrations, as well as the 
patient’s age and overall health (Wells et al. 1983).   Treatment modalities may 
consequently differ significantly from person to person. 
 Many options exist for the treatment of acute lymphocytic leukemia.  
These include chemotherapy, radiation, and bone marrow transplantation.  
Physicians may use one therapy or combine methods to treat particular cases of 
 ALL.  Multimodal therapy “creates synergistic and additive effects” not 
normally gained from the utilization of one therapy only (Goho 1993).   
 
Chemotherapy 
 Chemotherapy is the treatment currently chosen for most types of acute 
leukemias.  The first reported use of a chemical as an anti-neoplastic agent came 
from experiments with nitrogen mustard in a person with Hodgkin’s disease in 
1942.  Six years later, the discovery of remission induction by antifolates in ALL 
introduced chemotherapy as an anti-cancer agent.  These chemotherapeutic 
principles have led to curative therapies for the acute leukemias and 
lymphomas, successful treatments for the chronic leukemias and multiple 
myelomas, and have supplied the conceptual foundation for contemporary 
medical oncology (Chabner et al. 1999). 
 As the malignant process is distinguished by uncontrolled cell 
proliferation, it is understandable that chemotherapy should target DNA 
replication (Chabner et al. 1999).  Chemotherapeutic agents strive to prevent 
cancer cells from invading, multiplying, metastasizing, and destroying the host 
(Skeel and Khleif 2003).  The majorities of efficient cancer agents either generate 
chemical lesions in DNA or interfere with the synthesis of DNA.  The ultimate 
means by which cancer drugs produce cell death is uncertain.  Destructive 
mechanisms may range from apoptosis, or programmed cell death, to progression 
 of death following mitosis.  “While most antimetabolites and alkylating agents 
target DNA, other drugs attack the mitotic spindle (vinca alkyloids), inhibit 
protein synthesis (L-asparaginase) or induce cell differentiation (all-trans-retinoic 
acid)” (Chabner et al. 1999:186).   
 Chemotherapeutic drugs may be given orally, intravenously, or directly 
into a muscle.  These medicines are systemic, and they are able to move freely 
through the bloodstream and body.  Chemotherapeutic drugs are occasionally 
injected into the spine to access cerebrospinal fluid in the brain and spinal cord; 
this therapy is termed intrathecal chemotherapy (e.g., Mirro 2000).  
 The cell cycle of cancer cells is essentially that of normal cells.  Figure 4 
depicts not only the approximate time spent in each phase of the cycle, but also 
the main function of each period (Skeel and Khleif 2003). 
 Chemotherapeutic drugs that target DNA may be classified as either 
specific or nonspecific in reference to a phase of the cell cycle, and are ultimately 
dependent upon their interference with the mitotic cell cycle.  Figure 5 depicts 
the dynamics of chemotherapeutic interferences within the cell cycle (Goho 
1993).  Specific agents disrupt DNA synthesis (S phase) or cell division (M 
phase) (Goho 1993).  Early treatments should comprise multi-drug 
chemotherapeutic doses large enough to kill the majority of the leukemic cell 
population.  Agents commonly used in therapies are vincristine, prednisone, 
doxorubicin, methotrexate, asparaginase, and intrathecal cytosine arabinoside  
Fig. 4. Cell cycle times for normal human cell tissues.
Source:  Skeel RT, Khleif SN. Biologic and pharmacologic basis of cancer chemotherapy.  In:  Skeel RT.
Handbook of cancer chemotherapy. Philadelphia: Lippincott Williams & Wilkins,  2003, p. 3-11.
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 (Berg et al. 2000).  Table 1 lists various chemotherapeutic agents with their 
associated clinical complications (Rodman and Reed 2000). 
 Nonspecific agents target cells in all phases of the functioning cell 
cycle, with the exception of inactive cells in the G0 phase.  These drugs crosslink 
DNA bases to disrupt DNA replication.  These agents include alkylators 
(busulfan, chlorombucil, cyclophosphamide, melphalan, and nitrogen mustard), 
nitrosureas (BCNU, CCNU), antibiotics (actinomycin D, doxorubicin), DTIC, and 
cisplatin.   
Since tumor cells replicate asynchronously, they are not all 
in susceptible phases during the initial chemotherapy 
exposure.  Chemotherapeutic agents are eliminated rapidly, 
and a single dose does not affect tumor cells entering a 
susceptible phase at a later time.  Furthermore, chemo-
therapy works on first order kinetics, in which only a 
percentage of cells are killed with each dose, leaving some 
undamaged cells.  Chemotherapeutic agents are therefore 
administered in multiple (fractionated) doses so that tumor 
cells unaffected by the first dose are destroyed by following 
doses [Goho 1993:7]. 
 
Figure 6 depicts the effects of multiple dose chemotherapy on cancer cell 
numbers (Skeel and Khleif 2003). 
 As it aims to destroy cancer cells, chemotherapy often affects those 
normal cells or bodily organs that are undergoing reproduction at accelerated 
rates.  Mucosal linings, such as those of the mouth and intestines, as well as the 
skin, hair follicles and bone marrow, are often affected.  The overall goal 
involves selecting a chemotherapeutic agent that produces marked destruction  
 Table 1.  Chemotherapy side effects. 
 
        Late and/or Delayed 
Chemotherapy   Early Complications  Complications     
   
 
L-asparaginase Nausea and vomiting, allergic Unknown 
   reactions (such as rashes or 
   difficulty in breathing),  
   temporary diabetes, change in 
   mental status 
 
busulfan  Low blood counts; nausea,        Loss of normal menstrual 
   vomiting, and diarrhea  function; increased skin  
              pigmentation, lung  
        damage 
 
carboplatin  Tiredness; low blood counts Hearing problems; kidney  
             damage 
 
cisplatin  Hearing loss; nausea, vomiting, Hearing problems; kidney 
   diarrhea; vein and tissue       damage 
   damage if drug leaks from vein 
 
cyclophosphamide Nausea and vomiting; bladder   Bladder cancer or  
   damage; low blood counts; secondary leukemia 
   fluid retention; hair loss  (rare); decreased fertility 
 
cytarabine  Nausea and vomiting; mouth Decreased fertility 
   sores; low blood counts; fever;     
   skin rashes; irritated eyes;  
   seizures; diarrhea or liver  
   damage (from high-doses) 
 
daunorubicin, Nausea and vomiting; hair loss; Heart failure, skin or  
idarubicin,  mouth sores; low blood counts tendon deformities;  
doxorubicin,  resulting in anemia, bleeding pigmentation; secondary  
epirubicin,  or higher risk of infection; red- cancer 
   colored urine (not blood); skin 
   burn if drug leaks out of vein; 
   hair loss 
 
 Table 1. Continued 
 
         Late and/or Delayed 
Chemotherapy   Early Complications   Complications 
 
etoposide,   Nausea and vomiting; hair loss; Secondary leukemia 
teniposide  mouth sores; low blood counts; (uncommon) 
   allergic reactions (wheezing, 
   difficulty in breathing, skin  
   rashes swelling of lip); low blood  
   pressure 
 
hydroxyurea  Drowsiness; low blood counts; Secondary cancer 
   increased pigmentation; hair  
   loss 
 
ifosfamide  Hair loss; nausea and vomiting; Increased skin color; 
   bladder damage with bleeding; kidney damage 
   vein irritation; low blood  
   counts; confusion,  
   hallucinations 
 
mercaptopurine Nausea and vomiting; low  Unknown 
   blood counts; mouth sores; skin  
   rashes; liver damage 
 
methotrexate  Nausea and vomiting; low  Seizures, intellectual 
   blood counts; mouth sores;  impairment; kidney 
   skin rashes    damage (from high-dose 
              treatment); liver damage 
 
prednisone,   Temporary diabetes, high         Decreased growth;  
prednisolone,  blood pressure, changes in  decreased bone density; 
dexamethasone mood or behavior, acne;  joint destruction  
   increased appetite; weight  
   gain; peptic ulcer; muscle 
   weakness 
 
 
 
 
 
  
Table 1. Continued 
        Late and/or Delayed 
Chemotherapy   Early Complications  Complications 
 
thioguanine  Low blood counts; liver         Loss of normal menstrual 
   damage    function 
 
thiotepa  Pain at injection site; low blood Secondary leukemia 
   counts; dizziness; fever; hair 
   loss 
 
topotecan,   Diarrhea; low blood counts Unknown 
irinotecan  
    
vincristine,   Constipation; weakness;     Skin or tendon  
vinblastine  numbness or loss of reflexes; deformities 
   skin burn if drug leaks out of  
   vein; seizures; hair loss  
 
  
 Source:  Rodman J, Reed W.  Chemotherapy.  In Steen RG, Mirro J.  Childhood 
cancer.  Cambridge:  Perseus Publishing, 2000, p 141-51. 
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 of cancer cells, while providing minimal damage to normal cells (e.g., Skeel and 
Khleif 2003).   
 Side effects of chemotherapeutic therapy range in severity among patients 
with ALL.  As healthy marrow cells are destroyed along with tumor cells, 
various bleeding problems associated with diminished platelet counts, as well as 
anemia and infection may ensue.  Therapeutic action on the intestines and their 
linings often induce nausea and vomiting as common side effects of ALL.   Other 
symptoms of chemotherapy may include anaphylaxis, stomatitis as well as other 
oral complications, xerostomia, hair loss (alopecia), diarrhea, constipation, and/or 
an altered nutritional status due to a direct insult on the gastrointestinal tract 
(Tipton 2003). 
 Of particular importance to the dental profession are the symptoms of 
chemotherapy specific to the oral environment.  Many of the drugs used in 
cancer therapies are cytotoxic to the oral mucosa, interfering specifically with the 
replication, growth, and maturation of epithelial cells.  These toxic effects are 
expressed clinically by reduction, denudation, and ulceration of the mucosa 
surface.  Immunosuppressive actions of chemotherapeutic agents cause the host 
to be particularly susceptible to bacterial, fungal, viral, and mixed infections.  
Myelosuppressive actions of these agents can trigger neutropenia and 
lymphocytopenia, or severe decreases in blood neutrophils and lymphocytes.  
The most common sites of oral infections are the lips and tongue, followed by 
 the buccal mucosa, gingiva, palate, oropharynx, and occasionally the major 
salivary glands (Dreizen and Brown 1983). 
 
Radiation 
 Among the oldest and most efficient of cancer treatments, radiation 
therapy was recognized over a century ago for its ability to destroy both 
cancerous and healthy tissues (Merchant 2000).  Radiation therapy targets cancer 
cells while trying to avoid damaging normal tissues or organs (e.g., Goho 1993).  
However, cells and structures lying within the radiation beam can be injured as 
well.  While affecting rapidly dividing cancer cells more than normal cells, 
radiation therapy often also damages rapidly dividing healthy cells.  Skin and 
hair are the tissues most noticeably affected by radiation treatment, which can 
also result in skin lesions, burning, redness, and possible hair loss (Greene 2002).  
Dentofacially, radiation can affect bone growth, including “microvascular injury, 
fibrous replacement of marrow spaces, osteocyte death, and periosteal damage” 
(Kaste et al. 1994:95). 
 Radiation may originate from either an internal or external source:  
external radiation produces deep penetrating gamma and X-ray photons, while 
internal radioisotopes generate gamma and X-ray photons and beta particles.  
These beta particles impair DNA and amino acids either directly by ionizing 
 critical structural molecules or indirectly by first ionizing intracellular water 
used by the cells for vital processes (Goho 1993).  
 The ultimate effect of radiation therapy on an active tumor cell depends 
on its position in the cell cycle during therapy.  Cancer cells in the M, G1, and G2 
phases of the cell cycle are actively involved in mitosis and often sustain the 
most damage from radiation.  All cancer cells, even those in the G0 resting phase, 
may be affected by high doses of radiation.  Figure 5 depicts the effects of 
radiation, as well as chemotherapy reviewed above, on cells at various stages of 
the cell cycle (Goho 1993). 
 Radiation treatment also may be used to decrease tumor size, provide 
palliative therapy, or treat inoperable malignancies.  Therapy may be 
multimodal, through a combination of substances or involve a single agent.  
Commonly used radioactive agents include, but are not limited to:  Cesium 
(Cs137), Cobalt (Co60), Iodine (I131), Phosphorus (P32), Gold (Au198), Iridium (Ir192), 
Yttrium (Y90), and Palladium (Pa109) (Howard 2002). 
 Effects of radiation therapy vary immensely, but depend on the area of 
the body being irradiated as well as the schedule and dose of therapy.  Side 
effects may be either short-term, occurring within the first 90 days after 
treatment initiation, or long-term, occurring after the initial 90 days.  Short-term 
effects may include tissue destruction similar to a burn, discoloration of the skin, 
and/or weakness.  Long-term effects may include tissue atrophy, scarring, 
 impaired growth, as well as cancers secondary to initial diagnosis (Merchant 
2000). 
 
Bone Marrow Transplantation 
 Bone marrow transplantation (BMT), a newer type of therapy, can be 
used in conjunction with chemotherapy to enhance eradication of cancer cells.  
BMT therapy begins with considerable doses of chemotherapeutic agents (with 
or without radiation) to eliminate the bone marrow in the patient’s body.  
Healthy stem cells are then provided by a donor (allogeneic BMT) or harvested 
from the patient’s own marrow (autologous BMT).  A third type of transplant, a 
syngeneic BMT, involves an identical twin as a donor.  The healthy marrow is 
then supplied to the patient intravenously, with the new marrow intended to 
replace the diseased marrow (Horwitz 2000). 
 Significant research is being devoted to the newer forms of BMTs, namely 
autologous transplants.  After being removed from the patient’s body, the 
diseased marrow is treated with chemotherapeutic agents aimed at destroying 
cancer cells.  The treated marrow is then frozen to ensure preservation.  The 
patient then undergoes chemotherapy to kill all remaining cancer cells not 
removed in the marrow harvest.  The bone marrow transplant is concluded with 
the treated marrow intravenously placed back into the patient (Horwitz 2000). 
 
 Progression of Treatment 
 Treatment for ALL, though largely dependent on the mode of therapy, 
age of onset, and subtype of the disease, often progresses through four main 
phases:  (1) Remission induction therapy, the initial phase, uses 
chemotherapeutic agents to destroy a maximum number of leukemic cells while 
minimizing the “residual leukemic burden” (total number of leukemic cells in 
the body).  (2)  Consolidation or intensification therapy, the second phase, is 
used once the patient exhibits no sign of cancer and is in remission.  This phase 
consists of large doses of chemotherapy to destroy remaining cancer cells. (3)  
Central nervous system (CNS) prophylaxis, the third phase, is often combined 
with consolidation-intensification therapy.  This phase involves high dose 
therapy to both eliminate cancer cells in the CNS and prevent their spread to the 
spinal cord or brain.  Radiation therapy may or may not be used.  (4)  
Maintenance therapy, the fourth and final phase, spans the course of several 
years and exists solely to preserve remission of the disease (Silverman et al. 
1995). 
 
 
 
 
 
 Treatment Effects on the Human Body 
 
Effects on the Dentition and Oral Mucosa 
Multimodal cancer therapy for pediatric head and neck tumors may be 
associated with significant developmental orofacial abnormalities (Berkowitz et 
al. 1989).  Aggressive anti-neoplastic therapies, specifically chemotherapy and 
radiation often present significant detriment to the health and quality of life of 
long-term survivors of ALL (e.g., Kaste et al. 1997).  As cure rates continue to rise, 
dentofacial complications from various therapies become increasingly relevant 
(Goho 1993).   
The dental sequelae in patients treated for ALL are not surprising, 
because permanent teeth are undergoing active development during childhood, 
which is the time of peak incidence of ALL.  Human dentitions, both primary 
and secondary, begin their development early in life (e.g., Arey 1965; Corliss 
1976).  The primary dentition commences at approximately 6 weeks of gestation 
and maintains growth through three years of age, at which point the roots have 
completely formed (Kraus and Jordan 1965; Lunt and Law 1974).  The 
permanent dentition reaches its peak growth between the ages of four and six.   
Illness, trauma, chemotherapy, and radiation therapy may each affect 
dental development at any point prior to complete maturation.  The timing of 
the insult within the process of dental development is important.  An 
 understanding of these dentofacial changes and exploration of their causes is 
essential so that suitable diagnosis and treatment, as well as future prophylaxis 
may be well planned.  Still, because several therapies and agents are employed 
in a single patient’s treatment, the task of attributing a single dental abnormality 
to one specific agent or therapy is often impossible (Goho 1993). 
Sonis et al. (1990) stated that current ALL treatments in children often 
produced developmental disturbances of the craniofacial skeleton and 
permanent dentition.  The severity and degree of these disruptions depended on 
the child’s age at onset of ALL, dose of cranial radiation, and central nervous 
system treatment.  Children receiving treatment prior to five years of age had 
the most severe dental defects, indicating that developing, immature teeth might 
be at an increased risk for developmental disturbances compared to mature teeth 
(Sonis et al. 1990).   
Kaste et al. (1997) reported increased frequencies of hypodontia, 
microdontia, overretention of primary teeth, rampant decay, root stunting and 
taurodontism among the effects of ALL treatment.  Additionally, Goho (1993) 
confirmed chemoradiation’s connection to congenital tooth agenesis, precocious 
apical closure, and coronal hypocalcification, in addition to microdontia and root 
shortening.   
Kaste et al. (1997) evaluated the panoramic radiographs and clinical 
records of 423 ALL survivors to quantify the incidence, distribution, and 
 potential predisposing factors for dental abnormalities due to treatment for ALL.   
The following abnormalities were recorded during systematic examination of 
the panoramic radiographs:  root stunting, microdontia, hypodontia, 
taurodontia, and over-retention of the primary teeth.  
Hypodontia, or the incomplete development of a full complement of 32 
permanent teeth, was noted in some children in a study by Kaste et al. (1997). 
Microdontia, the development of abnormally small teeth, occurred in about 20 
percent of this sample.  While fairly rare in the general population, microdontia 
of maxillary lateral incisors and of third molars occurred in nearly five percent of 
the ALL sample.  Kaste et al. (1997:795) stated: 
Hypodontia and microdontia can cause abnormal spacing 
and drifting of teeth, potentially resulting in poor dental 
alignment, malocclusion, and dysfunction of the 
temporomandibular  joint.   In addition,  hypodontia  or root  
stunting preclude adequate orthodontic anchorage and place 
these teeth at added risk for the damaging effects of gingival 
and periodontal disease.  
 
Over-retention of primary teeth, the failure to shed primary teeth in a 
timely manner, occurred in roughly four percent of the sample.  Over-retention 
of primary teeth involves not only the problem of retaining a primary tooth, but 
also the delayed eruption of the succedaneous tooth.  Though controversial 
whether over-retention is due to chemoradiation, this abnormality is often 
associated with the following systemic conditions:  Down syndrome, 
hypopituitarism, and hypothyroidism (Kaste et al. 1997).  Goho (1993) reviewed 
 the overall effects of chemotherapy and radiation treatments and stated that any 
factor (or treatment modality) affecting dental development might also influence 
the relative progression of the ensuing teeth. 
Extensive carious lesions present as frequent dental anomalies in children 
treated for cancer.  Kaste et al. (1998) evaluated a retrospective sample treated for 
neuroblastoma, and noted that many of these patients had inadequate oral 
hygiene habits and increased carbohydrate intakes.  Kaste et al. (1998:24) stated:  
Dietary factors and parent permissiveness may also 
contribute to the increased dental caries in pediatric 
oncology patients.  Frequently these children develop 
stomatitis and oral mucosal ulcerations.  They may prefer 
sweet foods, thereby further promoting tooth decay.  
Medically compromised patients often require high 
carbohydrate diets in order to maintain caloric intake.  
 
Extremely ill patients may not feel well enough to concentrate on their 
oral health.  Additionally, young children depend on their parents for oral 
hygiene maintenance.  Oral health and prophylactic care should be a chief 
priority when addressing treatment concerns for oncology patients (Kaste et al. 
1998).   It is necessary to have a comprehensive understanding of the patient’s 
medical status as well as any plans for cancer treatment.   
Root stunting, though rare in the general population, occurred in nearly 
25 percent of the same sample evaluated by Kaste et al. (1997).  The most 
frequently affected teeth, the molars, were supposed to most frequently sustain 
damage because of their developmental status at the early age of treatment.  As 
 the roots of the permanent molars had not developed fully before treatment was 
initiated, they were more frequently and severely affected by oncotherapy.  In 
contrast, development of the permanent incisors, premolars, canines, and 
crowns of molars was nearly complete by the time treatment begun in most 
patients (Kaste et al. 1997). 
Taurodontism, the presence of noticeably wider and lengthened pulp 
chambers, can occur in either the primary or permanent dentitions (Pindborg 
1970).  This anomaly is most often attributed to a “delay in the development and 
proper positioning of Hertwig’s epithelial root sheath after formation of the 
tooth crown resulting in the apical displacement of the pulpal floor and 
furcation areas” (Llamas and Jimenez-Planas 1993).  Llamas and Jimenez-Planas 
(1993) suggest that genetic factors might affect the timely development of 
Hertwig’s root sheath in cases of nontreatment-related taurodontism.  
Commonly found in only one to 11 percent of the general population, 
taurodontism was identified in approximately 17 percent of the study.  Within 
the sample exhibiting taurodontism, 98 percent were under the age of eight 
years old leading the researchers to speculate that cancer therapy in young 
patients might promote taurodontism.  Clinically, teeth exhibiting taurodontism 
have markedly decreased root surface, are more susceptible to periodontal 
disease, and are less agreeable to orthodontic treatment (Kaste et al. 1997). 
 Root agenesis, or early apical closure, may be attributed to radiation 
therapy.  While it represents a form of systemic therapy, chemotherapy would 
not simply affect one tooth class; instead, it would affect whichever teeth are 
undergoing crown-root formation.  Goho (1993) reported a patient in whom 
early apical closure of the roots of the first and second molars correlated with 
root development at 4.0 to 4.5 years old, the age at which the child began anti-
neoplastic therapy. 
 
Effects of Radiation on the Head and Neck 
The processes of enamel formation, amelogenesis, and the process of dentin 
formation, dentinogenesis, are affected by radiation directed at or near the mouth.  
Orofacial structures, including the teeth and mucosa, receive approximately half 
the radiation when located near the exposure, while radiation directed at distant 
structures provides no damage to the developing dentition (Goho 1993).  Figure 
7 depicts radiation therapy fields commonly used in the treatment of head and 
neck cancers (Berkowitz et al. 1989).  In the past, when dentofacial damage was 
anticipated, physicians commonly provided bilateral radiation to balance facial 
skeletal growth disturbances and preclude hemifacial hypoplasias (Goho 1993).  
Nwoku and Koch (1995) suggest that while the skin and mucosa are sensitive to 
radiation, both show extensive regenerative power, which probably explains 
why bone seems to suffer more injury than the epidermis. 
 
 
 
 
Fig. 7. Common radiation fields used in the treatment of cancers of the head. 
 
Source: Berkowitz RJ, Neuman P, Spalding P, Novak L, Strandjord S, Coccia PF. 
Developmental orofacial deficits associated with multimodal cancer therapy:  
case report.  Ped Dent 1989;11:227-31. 
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 Overall damage depends on the dose delivered, regardless of the  
therapeutic means employed.  Sonis et al. (1990) mentioned doses of 2,000 to 
4,000 cGy in both animals and humans have been shown to induce tooth and 
root “dwarfism,” root foreshortening, hypoplasia, microdontia, and atypical root 
morphology.  Prior to morphodifferentiation and mineralization, radiation 
treatments may result in arrest of the developing dental tissues.  Equally, at later 
stages of development, dental malformations or arrested development have 
been observed (Sonis et al. 1990).  Low doses of radiation may cause little or no  
damage to developing ameloblasts and odontoblasts, while high doses induce 
rapid cell death.  Radiation affects cells in all stages of the cell cycle, whether 
proliferating or not.  Dental development in humans has been revealed to  
sustain localized damage at 400R.  However, the dose at which odontogenic cell 
death occurs unequivocally is still unknown (Goho 1993). 
 
Effects of Chemotherapy on the Head and Neck 
Chemotherapeutic effects depend on both the dose and the repetition of 
drugs.  While radiation therapy affects cells in all stages of the cell cycle, 
chemotherapy only impacts actively dividing cells.  Additionally, while 
radiation therapy damages only those cells in its path, chemotherapy is more 
extensive in its effects.  Chemotherapy not only harms cells near or inside a 
tumor, it also affects cells and organs located far from the desired sites.  The 
 following results of chemotherapeutic treatments have been documented:  
enamel defects, obstructed root development, and reduced dentin formation.  
Goho (1993) stated that eruption rates have shown no detrimental effects from 
chemotherapy. 
Chemotherapeutic agents exhibit short half-lives and are eliminated 
quickly from the bloodstream.  Consequently, effects on odontoblastic cells can 
be fatal, but are most often merely harmful (Goho 1993).   
 
Endocrinologic Complications 
 As radiation and chemotherapeutic agents often fail to differentiate 
between metabolically active cells and neoplastic cells, numerous dental and 
craniofacial abnormalities have resulted from such anti-neoplastic treatments.  
However, Sonis et al. (1990) noted that an altered hypothalamic-pituitary 
function may result in decreased growth hormone production.  Consequently, 
odontogenesis and craniofacial development might be adversely affected (Sonis 
et al. 1990). 
 When considering acute lymphoblastic leukemia, factors commonly 
affecting growth may include chemotherapy, irradiation, infection, poor 
nutrition, or the actual disease itself.  “Cranial irradiation, leading to growth 
hormone (GH) deficiency, has been implicated as the main etiological agent in 
growth retardation following the treatment of brain tumors” (Clayton et al. 
 1988:460).  Previous growth studies of ALL indicated that GH replacement 
therapy to be needed only when chemotherapeutic dose levels exceeded 2,400-
2,500 cGy (Clayton et al. 1998).   
 Hypopituitarism has been shown to follow high-dose irradiation of both 
intra- or extracranial tumors (Tan and Kunaratnam 1966; Shalet et al. 1975; 
Richards et al. 1976).   Smaller doses of cranial irradiation are often used in ALL, 
with hopes that these children sustain no considerable effects to the 
hypothalamic-pituitary axis.  However, Schiliro et al. (1976) and Shalet et al. 
(1976) reported that these children may be at an increased risk of growth 
hormone (GH) deficiency, with their ultimate response in proportion to the 
“dose and fractionation of the irradiation” (Swinft et al. 1978:890).  Additionally, 
Shalet et al. (1976) reported there may possibly be a progressive drop in GH 
response with increasing time after cranial irradiation.  Interestingly, Kirk et al. 
(1987) noted that “idiopathic” GH deficiencies occur more commonly in males, 
so perhaps the male hypothalamus is more vulnerable to other abnormalities of 
GH regulation (1987;192).  Lawrence et al. (1971:893) stated,  
The site of radiation damage to the hypothalamic-pituitary 
axis is unknown.  The pituitary is generally considered to be 
relatively radioresistant, probably because histological 
pituitary cell necrosis is rarely seen after irradiation.  Radio-
therapy may however alter pituitary cell function, increase 
permeability of the blood-brain barrier to potentially 
encephalotoxic drugs or damage the vasculoglial tissues of 
the hypothalamic-pituitary axis affecting the synthesis and 
release of hypothalamic releasing hormones. 
 
  Kirk et al. (1987) reported high rates of only diminished stature in children 
treated for ALL, however overall growth retardation was not demonstrated.  
Stature had decreased by more than one standard deviation in 32 percent of 
survivors at 4 years post-diagnosis and in 71 percent at 6 years post-diagnosis.  
Standard deviation scores were constructed as deviation measurements from the 
population mean.  Kirk et al. (1987) also mentioned growth of younger children 
and those children especially tall for their age at diagnosis were more 
susceptible to reductions in overall stature.  
 Clayton et al. (1998) also evaluated changes in stature.  82 children treated 
for ALL were evaluated who achieved complete and continuous first remission 
following cessation of treatment.  Forty-eight children received prophylactic 
cranial irradiation at a total dose of 1,800 cGy and 38 children received a dose of 
over 2,000 cGy.  Chemotherapy spanned two to three years, with both groups of 
children showing a comparable decrease in height standard deviation.  The 
greatest decrease in height occurred within the first year of diagnosis, whereas, 
height standard deviation scores of both groups increased significantly upon the 
completion of treatment.   Clayton et al. (1998) concluded that while 
chemotherapy did contribute significantly to diminished stature in children with 
ALL, mean loss in the majority of children was not high enough to substantiate 
GH replacement therapy.   
  Swinft et al. (1978) noted the importance of a regular review of not only 
the neoplastic condition, but also detailed surveillance of growth and 
development.  Endocrine investigation is essential only if growth and 
development are cause for concern. 
  
Clinical Effects and Prophylactic Care 
Orthodontic tooth movement, prosthetic replacement of missing teeth, 
periodontal health, endodontic procedures, and prophylactic home care may be 
compromised after therapies in children treated for ALL .  The achievement of 
optimal dental health is increased if the clinician is mindful of dental 
development at the time of treatment as well as the type and quantity of 
treatment delivered (Goho 1993). 
A panoramic radiograph, at minimum, should be obtained prior the 
beginning anti-neoplastic treatments.  This radiograph enables clinicians to 
locate potentially vulnerable dental structures and establish a baseline of oral 
health specific to that patient.  An additional panoramic radiograph should be 
obtained at the conclusion of treatment.  This radiograph details damage to 
dental structures, allows for quantification of its severity, as well as aiding in an 
overall treatment approach to restore dental health (Goho 1993). 
 The prognosis for the correction of craniofacial abnormalities caused by 
anti-neoplastic therapies is guarded.  Clinicians are often unable to formulate an 
 ideal treatment plan for these patients.  Quite often then, treatment is 
compromised at the beginning.  Sonis et al. (1990:2651) reported problems 
specific to mandibular growth potential: 
Moreover, mandibular growth remains retarded, leaving 
patients  with a  skeletal  disharmony between the two jaws.   
Conventional orthodontic correction of these problems often 
relies upon mandibular growth, although an attempt is 
made to retard maxillary growth therapeutically, allowing 
the mandible to “catch up” to the maxilla.  Because the 
mandibles of our patients lacked intrinsic growth potential, 
correction may only be achieved with orthognathic surgery. 
 
Human Growth and Development 
 Growth and development describe the changes an individual progresses 
through from conception until death.  Growth is defined as a change in physical 
size of the organism as a whole or any of its parts.  Examples of such growth 
may be an increase in height, an increase in weight, or an increase in arch 
circumference.  Growth is not necessarily an increase, but may denote a decrease 
in size such as formation of the digits of the hand through selective cell death 
(apoptosis).  When considering neoplastic conditions such as ALL, “growth is a 
sensitive measure of a child’s health and would thus be assumed to be affected 
in these children for multiple reasons: severe disease, irradiation of the skull, 
cytostatic treatment and perhaps poor nutrition” (Berglund et al. 1985:530). 
 Development is defined as a change in proportion and/or an increase in 
complexity.  One such example includes the progression of fine motor skills and 
 dexterity throughout life.  Development indicates not only a change in shape of 
the entire body, but also individual anatomical structures. 
 Growth of the postnatal individual may be divided into four major 
intervals:  infancy, childhood, adolescence, and adulthood.  Each interval is 
distinguished by its own characteristic rate of growth.  Figure 8 depicts velocity 
of growth for these four intervals of growth (Tanner 1962). 
 
Scammon’s Growth Curves 
 Richard Scammon (1927) described four main patterns of postnatal  
growth.  These four patterns, known as the “Scammon Curves” and 
diagrammed in Figure 9, are:  general (or somatic), neural, lymphoid, and  
genital.  These curves assume birth as the starting point (= 0%) and 20 years of 
age as “maximal adult dimensions and size” (= 100%). 
 The general or “somatic” pattern of growth represents growth of the body 
as a whole and encompasses such measurements as height, weight, et cetera.  
This pattern has been divided into four parts:  (1) a period of rapid growth in 
infancy at 0 to 5 years of age; (2) fairly uniform increments during early and 
middle childhood at 5 to 11 years of age; (3) a rapid parapubertal increase at 11 
to 16 years of age; and (4) a final period of slower growth during late 
adolescence and early childhood at 16 to about 35 years of age.   
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Fig. 8. Human growth velocity chart for somatic tissues partitioned into
the four major intervals of postnatal growth. (Drawing provided by Dr.
E. F. Harris.)
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Fig. 9. Scammon’s four tissue-specific patterns of postnatal growth.  The scheme
is that size is standardized to 0% of adult size at birth and 100% of adult size
occurs by 20 years of age.  (Drawing provided by Dr. E. F. Harris.)
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  Tissues reflecting the neural pattern of growth include the brain and 
associated structures (cerebellum, pons, and medulla), the eyeball and the pineal 
gland.  The two parts of the neural growth curve are:  (1) a period of rapid 
growth subsequent to birth at 0 to 5 years of age; (2) a period of slow growth 
leading into maturity from age 6 forward.  The human brain has achieved 
approximately 95 percent of its growth by age 7 or 8. 
 The lymphoid pattern of growth involves the weights of the thymus, 
adenoids, tonsils, mesenteric lymph nodes, as well as the number of Peyer’s 
patches in the small intestine and lymphoid follicles in the appendix.  The three 
parts of the lymphoid curve are:  (1) a rise of greater velocity in infancy and early 
childhood to an apex at puberty at 0 to 11 years of age; (2) a decrease in size from 
late childhood to adulthood at 12 to 20 years of age; and (3) maintenance of 
small size during adulthood commencing at age 20.  Quite commonly the second 
phase fails to occur; that is, lymphoid tissues such as the adenoids and tonsils do 
not decrease adequately in size.  This failure often presents problems for 
orthodontists and pediatric dentists, as these children may develop habits of 
mouth breathing which may adversely affect the dentition and related skeletal 
structures. 
 The genital pattern of growth encompasses the testis, ovary, epididymus, 
uterine tube, prostate, and seminal vesicles.  The three parts of the this curve are:  
(1) a slow rise in infancy followed by a latent period at 0 to 13 years of age; (2) a 
 rapid increase from the prepubertal period, through adolescence into early 
maturity at 13 to 20 years of age; and (3) an extended period of maintenance 
throughout adulthood beginning at age 20.  The rapid rise in the genital curve 
represents the increase various sex hormones which produce “sexual maturity” 
in both males and females. 
 
Intervals of Human Growth 
 The many diverse tissues and structures of the human body have 
extremely different patterns of growth, as is illustrated by Scammon’s four 
growth patterns.  Cells of organs, as well as the organ as a whole, are highly 
dependent on their environment for nutrient supply and removal.  Organs may 
appear particularly vulnerable during stages of increased or important growth, 
such as rapid cell proliferation.  These times of greatest vulnerability are termed 
critical periods.  Critical periods are those times in a tissue’s life during which the 
opportunity for irreversible damage are greatest (Smith 1977). 
 The development of a particular organ or structure progresses through 
four distinct stages depicted in Figure 10.  This figure is representative of total 
DNA and total protein content throughout life.  These stages are: (a) 
hyperplasia, (b) a mixed period of hyperplasia (multiplicative growth) and 
hypertrophy (dimensional growth), (c) hypertrophy, and (d) maturity and aging.  
The most critical period of growth corresponds with the hyperplastic phase, in  
Fig. 10. Stages of development in the growth and differentiation of an organ
tissue. (Figure provided by Dr. E.F. Harris.)
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 which cells are mostly rapidly proliferating.  The interval of hyperplasia and 
hypertrophy represents a “sub-critical” period. 
 As Scammon’s growth curves illustrate, the various different tissues and 
organs of the body develop and mature at various rates.  Thus, these different 
structures possess separate critical periods and periods of maximum  
vulnerability.  Figure 11 depicts the critical period for several major organs of the 
body. 
 
Physiologic Age Assessments 
 Bones in the skeleton may be analyzed throughout an individual’s life—
from birth, through skeletal maturation, finalized with the end of life (Greulich 
and Pyle 1959).  “Maturational status can have considerable impact on diagnosis,  
treatment goals, treatment planning, and the eventual outcome of orthodontic 
treatment“ (Moore et al. 1990:33).  Chronological age, or a person’s age in calendar 
years, serves as the standard by which most laypersons gauge maturity.  
However, this measurement often does not adequately reflect a person’s 
biological maturity or developmental status, particularly when considering 
those periods of infancy or childhood.  The majority of children may be seen as 
“average maturers,” with a strong association between their chronological and 
biological ages.   Some children, however, may appear developmentally delayed, 
and these are termed “late maturers.”  Conversely, “early maturers” is the term  
Fig. 11. Critical periods for major organs and tissue systems. (Figure
provided by Dr. E.F. Harris.)
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 that describes those children whose developmental growth precedes their 
chronological age (Tanner 1962). 
 The framework or connective tissues of the body serve as a standard 
applicable to general bodily development.  The skeleton has been chosen in the 
past merely because radiographic technique provides “a ready, easily applicable  
and noninjurious method of determination.  Skeletal age thus becomes a 
measure of bodily maturation and not a goal in itself” (Todd 1937:13).  Skeletal 
or biological age, also termed “developmental age” and “physiological age,” 
reflects the level of maturity achieved by the individual.  While a number of 
methods exist by which biological age may be assessed, two provide particular 
information to the dental profession.  These methods are a “bone age” 
evaluation based on hand-wrist radiographic analysis and a “dental age” based 
on formation of the crowns and roots of developing teeth as seen 
radiographically (e.g.,  Demirjian 1978). 
Average bone or skeletal ages illustrate the maturation status in which 
normal children, male and female, match up with their corresponding calendar 
or chronological age (Jimenez-Castellanos et al. 1996).  Similar to the growth of 
organs in the human body, bones of the skeleton progress through their 
morphological development at different points in time.  In the child, new 
(secondary) ossification centers appear over a span of time, and existing ones are 
 remodeled.  Knowing initiation times and morphological changes of bones in the 
hand and wrist provide a means of relating skeletal age to chronological age.   
The following excerpt was taken from Greulich and Pyle’s text, 
Radiographic Atlas of Skeletal Development of the Hand and Wrist: 
The development of individual bones of the hand and wrist 
as well as those of other regions can be impaired by febrile 
and other illnesses and they seem to be especially vulnerable 
to   such   deleterious  influences   at  certain  stages   of  their 
differentiation.  A hand-wrist film made of such a child 
before the affected ossification center or centers have made 
up their developmental deficiencies reveals the skeletal 
imbalance that the illness has produced. The hand-film can 
provide a record of past illnesses and a measure of the 
severity of their impact on the developing skeleton, a 
reflection of their impact on the total organism.  Knowing 
the rate at which these skeletal deficiencies are corrected, as 
determined by subsequent X-ray examinations, is helpful in 
appraising the child’s progress toward complete recovery 
[Greulich and Pyle 1959:18]. 
 
 Hand-wrist radiographs are commonly used in the assessment of 
biological age because (1) the hand and wrist are reasonably accessible, (2) those 
vital organs particularly at risk to radiation damage are not in close proximity, 
(3) there are several bones (19 diaphyseal bones, 8 carpals, plus the distal radius 
and ulna) by which developmental maturity may be measured.  Technique 
involves placing the hand directly on an X-ray cassette, with fingers spread 
slightly apart.  Source-to-film distance should be at least five feet.  Figure 12 
depicts the bones of the hand-wrist complex. 
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Fig. 12. Schematic of the hand-wrist bones as visualized on a dorsoventral
radiograph.  (Diagram provided by Dr. E. F. Harris.)
 Development of Hand-Wrist Standards 
Sydney Rowland was the first to mention use of hand-wrist radiographs 
in children (cited in Pyle et al. 1971).  Rowland used radiographs to formulate 
indicators of skeletal maturity and published his description of the “shadows of  
the hand bones of a nine year old girl” on April 2, 1896.  Just four months earlier, 
in late 1895, the scientific community had been introduced to the discovery of X-
rays by the physicist Wilhelm C. Röentgen (Pyle et al. 1971).  
 A total of 29 bones exist in the hand-wrist complex by which a 
physiological age assessment may be made.  Nineteen phalanges are  
present in the hand, three in each of the four fingers (proximal, middle, and 
distal), while only two exist in the thumb (proximal and distal).  Each ray has 
one metacarpal, while the wrist has eight carpals.  Each diaphysis has a  
corresponding epiphysis on the distal end of each metacarpal and the proximal 
end of each phalange.  Thus, 21 epiphyses plus 8 carpals lends a total of 29 bones 
available for evaluation in a hand-wrist film. 
In 1929, under the direction of T. Wingate Todd of Case Western  
Reserve University School of Medicine, the Brush Foundation began work  
on preliminary human growth and development studies.  When the study 
began, there were no provisional standards by which to compare measurements.  
The project commenced in 1931, with three-month-old infants enrolled in the 
 study, and concluded in the summer of 1942.  The children, ranged in age from 
three months to fourteen years (Greulich and Pyle 1959).   
The children accepted for study were selected on the basis of 
their freedom from gross physical or mental defects on the 
promise of their parents to permit their continued 
participation until the completion of the project.  Since, in 
addition, they were admitted only on application of a 
pediatrician, their families were somewhat above average in 
economic and educational status.  All the children were 
White, all had been born in the United States, and almost all 
were of North European ancestry [Greulich and Pyle 
1959:xii].  
 
Children in the study were observed at three-month intervals during their 
first year after birth, at six-month intervals from twelve months to five years of 
age, and once a year thereafter.  The series, published by Todd in 1937 as his 
Atlas of Skeletal Maturation of the Hand, included from two to twenty-one hand-
wrist films made at consecutive examinations of each of 1,000 children.  While it 
included information gathered from children in the Brush study, Todd also 
incorporated films that he and his associates had made of other children from 
various agencies and schools throughout the Cleveland, Ohio area (Greulich and 
Pyle 1959). 
Greulich and Pyle undertook the task of updating and extending their 
own radiographic norms for skeletal age of adolescent males and females.  Their 
work, first published in 1950, was based on the 1930’s work of T. Wingate Todd 
at Case Western Reserve University.  When preparing their standards for 
skeletal age in their second edition, Greulich and Pyle (1959) included not only 
 Todd’s X-ray films through 1936, but also those which were obtained during the 
subsequent six years of the Brush study.  Greulich and Pyle’s study arranged 
substantial groups of children chronologically to provide measurements they felt 
best represented children of that age.  Their atlas differed from Todd’s in that it 
included fewer standards.  “It is our opinion, that, after the age of five years, in 
both boys and girls, the skeletal development of the hand does not proceed 
rapidly enough to require standards at more frequent than approximately 
annual intervals except about the time of puberty” (Greulich and Pyle 1959:xiii).  
Figure 13 depicts an example of a hand wrist film used in assessment of skeletal 
age (Greulich and Pyle 1959).   
Greulich and Pyle’s radiographic assessment of the hand-wrist complex 
involved two specific steps, the atlas and the bone specific methods.  The atlas 
method involved comparing a hand-wrist film with the standard of the same sex  
and nearest chronological age.  The film would then be compared with adjacent 
standards, both older and younger than the one is of the nearest chronological 
age.  Finally, the standard which appears most closely to resemble the film in 
question is chosen.  This first method is termed the atlas method (Greulich and 
Pyle 1959). 
After selecting the appropriate GP2 standard via the atlas method, the 
examiner should proceed to make a more detailed comparison of the individual 
bones and epiphyses visible in them.  The bones of the hand-wrist complex  
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Fig. 13. Example of a dorsopalmar hand-wrist radiograph.  The fingers are 
relaxed.  The radius is to the right (lateral) in this view. This particular example 
if of a 6 year-old American white boy. All of the epiphyses are mineralized, 
though that of the ulna is still small and sesamoid-shape.  Seven of the eight 
carpals are evident; the pisiform, if forming, is superimposed to the palmar 
(anterior) of the triangular bone.  (Figure provided by Dr. E. F. Harris.) 
 should be considered in a regular order.  That is, one should begin at the distal 
ends of the radius and ulna, proceed next to the carpals, then to the metacarpals,  
and finally to the phalanges.  Similarly, one should examine the carpals in a 
regular sequence—in their usual order:  Capitate, Hamate, Triquetral, Lunate, 
Scaphoid, Trapezium, Trapezoid, Pisiform.  This method is termed the bone-
specific method (Greulich and Pyle 1959). 
If an individual bone in the film to be assessed is in 
the same stage of development as the corresponding bone in 
the standard selected for the detailed comparison, it should 
be given the skeletal age that has been assigned to that bone 
in that standard.  If it appears to be either less advanced or 
more advanced that its counterpart in that standard, it 
should be compared with the same bone in its adjacent 
standards.  The proper skeletal age to be assigned to it is 
that which is given in the standard to the corresponding 
bone that shows the same degree of development.  If none is 
found that corresponds exactly in developmental status 
with the bone to be assessed, its skeletal age should be 
estimated from that of those which it most closely 
resembles. 
The developmental status of all bones of the hand to 
be assessed will occasionally correspond exactly to that of 
some one hand standard in this Atlas.  When such is the 
case, the skeletal age of that standard is the skeletal age to be 
assigned to the child’s hand.  If, however, its developmental 
status does not correspond exactly to that of any one 
standard but is, rather, intermediate between those of two 
adjacent standards, the age assigned to the film should be 
correspondingly intermediate between the ages of the two 
standards which it most closely resembles [Greulich and 
Pyle 1959:35-36]. 
 
 In search of a standard appropriate for an independent study, Alice M. 
Waterhouse and Tavia Gordon (1963) found that S. Idell Pyle was preparing a 
 reference standard that included the hand-wrist complex.  Her standards were 
based on the films of children enrolled in two growth studies conducted 
independently from 1929 to 1962 by the Brush Foundation of Cleveland, Ohio, 
and the Department of Maternal and Child Health in the Harvard School of 
Public Health in Boston, Massachusetts (Pyle et al. 1971).  These standards for the 
hand and wrist were more complete chronologically than any other standard 
currently in use in 1964.  Standards were arranged evenly at six-month intervals 
from ages three to thirteen years, and closely resembled the original standards 
set by T. Wingate Todd in 1937.  The key difference was that Todd’s atlas 
included two separate series of films and age equivalents, one for males and one 
for females.  Thus, in 1962, at the urging of Drs. W. W. Greulich and H. C. Stuart, 
Dr. Pyle was employed to prepare a single series of films that would provide 
standards for both sexes [as long as bone age equivalents for each sex were 
assigned to each bone.]   Dr. Pyle’s study was included in the National Health 
Survey, and was supported by the National Center for Health Statistics (Pyle et 
al. 1971). 
 In constructing their standards for hand-wrist bone ages, Pyle et al. 
proposed two objectives:  (1) to select representative films that would offer a 
variety of discernible features of developing hand-wrist bones—a series spaced 
at three, six, or twelve month, and (2) to relate these structures as accurately as 
 possible to the chronological level at which they usually appeared in the median 
position for the Cleveland boys and girls (Pyle et al. 1971). 
 Tanner et al. formulated two successive methods of estimating HW bone 
ages that were believed to be “more flexible and deriving from a more solid 
mathematical base than the Greulich-Pyle method” (1975:v).  The first analysis, 
named TW1, was published in 1962 and the second analysis, labeled TW2, was 
published in 1975.  The TW2 analysis was a follow-up to Tanner, Whitehouse, 
and Healy’s 1962 analysis in which “each bone of the hand and wrist was 
classified separately into one of eight or nine stages, to which scores were 
assigned”(Tanner et al. 1975:v).  These scores were then added to provide the 
skeletal maturity estimate.  The ordinal scale for rating the distal radius is 
depicted in Figure 14.  Grade A represents the appearance of the diaphysis 
before any radiographic formation of the epiphysis is detectible.  Grade B  
corresponds to the initial development of an ossification center in the  
cartilaginous precursor.  Grades B through I depict progressive maturation and 
development of the epiphysis, ultimately ending with its capping and fusion 
with the diaphysis.  Growth is completed at fusion, with the exception of minor 
remodeling that can occur at the subchondral articular surfaces.  The TW2 
analysis formulated by Tanner et al. was a revised version of the TW1 (Tanner et 
al. 1975). 
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Fig. 14. The eight-grade ordinal scale of maturation of the distal radius.
Source: Tanner JM, Whitehouse RH, Marshall WA, Healy MJR, Goldstein H.
Assessment of skeletal maturity and prediction of adult height (TW2). New
York: Academic Press, 1975.
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 Fishman also formulated a scheme for assessing HW bone age that was 
published in 1982.  His analysis was based on and involved a simplified 
approach to Greulich and Pyle’s 1959 standards (GP2 standards).  He noted both  
the importance of hand-wrist films in measuring bone age and affirmed their 
clinical importance in applications relating to dentofacial diagnosis and therapy.  
He proposed four phases of bone maturation, located at six sites on the thumb, 
third finger, fifth finger, and radius.   These sites are the adductor sesamoid of  
the thumb, the distal, middle and proximal phalanges of ray three, the middle 
phalanx of ray five, and the epiphysis on the distal end of the radius.  
Fishman’s assessment is based on 11 grades of maturity, and these are 
depicted in Figure 15 as a flow chart by which the patient’s stage of  
development is reached.  The following excerpt was taken from Pyle et  
al.’s A Radiographic Standard of Reference (1971:26): 
The natural process of ossification begins in and spreads 
from specific sites in each bone, namely, its growth centers.  
Each expanding osseous mass in a cortex is surrounded by a 
vital,   expanding    cartilaginous   ‘rim’    which   is    always  
differentiating ahead of the ossifying area until the bone 
attains its adult shape and size.  Accordingly, all skeletal 
maturity indicators are preformed in cartilage.  Since the 
cartilaginous portion of any cortex is translucent to X-rays, 
the entire growing bone is not shown in a radiograph. 
 
 Biological maturity is of importance to the dental profession.  While 
average maturing children represent the norm, the clinician should recognize 
those children particularly late or early in their development.  That is, those  
Fig. 15. Fishman’s 11-grade scheme used to assess skeletal maturity
from a hand-wrist radiograph. (Diagram provided by Dr. E. F.
Harris.)
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 children fall outside the norms when their biological and chronological ages do 
not correspond.  Additionally, certain dental treatments, particular orthodontics, 
often rely heavily on the individual’s growth potentials.  
 
Effects on Human Growth and Development 
 
With improved cure rates for acute lymphoblastic leukemia 
(ALL) and the increasing number of long-term survivors, it 
is important to determine whether clinically meaningful 
growth retardation occurs in these children and whether 
this adverse outcome is predictable and potentially 
preventable [Schriock et al. 1991:400]. 
 
Stature and Weight 
Anti-neoplastic therapies have been evaluated for their effects on the 
overall tempo growth and development.  Various research endeavors focused on 
the effects on bone age, while other studies concentrated on therapeutic effects 
on stature and weight.   
Sklar et al. (1993) analyzed changes in height due to cranial irradiation for 
127 children (68 females, 59 males) treated for ALL.  Three treatment groups 
were studied:  38 patients who received no cranial irradiation, 36 patients who 
received cranial irradiation of 1,800 cGy, and 53 patients who received 
irradiation of 2,400 cGy.  Mean age at diagnosis of the patients was 6.4 years (sd 
= 0.25 years).  Results of the study indicated a significant overall decrease in 
height standard deviation scores (SDS) for all three treatment groups from 
diagnosis until the end of therapy and from the end of therapy until a final 
 evaluation.   Patients in the 2,400 cGy treatment group had the greatest decrease 
in height SDS, followed by those patients in the 1,800 cGy group.  Those patients 
who did not receive irradiation showed the least reduction in height SDS.  Sklar 
et al. (1993) mentioned that younger age and female sex were closely associated 
with a significant decrease in height SDS for irradiated patients.  A mean loss in 
height SDS nearly twice that seen for others with similar dose treatment was 
observed in female patients < 4 years of age at diagnosis.  Growth hormone 
replacement therapy was not recommended by these authors for most ALL 
patients.  However, female patients less than 4 years old were shown to be at 
high risk of sustaining growth retardation (Sklar et al. 1993).  Dalton et al. (2003) 
proposed that an earlier onset of puberty in females might improve height at the 
time of puberty because of acceleration in the rate of growth, but then might 
compromise final height by decreasing the time interval for growth. 
Katz et al. (1993) evaluated final adult height of 109 patients treated for 
acute lymphoblastic leukemia between 1974 and 1981.  Fifty-eight patients 
received no cranial irradiation, while 51 received 2,400 cGy of cranial irradiation.  
Prior to treatment, both groups had height distributions similar to those of the 
U.S. population.  Mean age of the patients at diagnosis was 7.8 years (sd = 4.2 
years).  Final examination of the 51 patients who received cranial irradiation in 
addition to chemotherapy showed a mean height standard deviation score of -
1.04, which corresponded to a median height reduction of 6.3 cm in females and 
 7.0 cm in males.  In contrast, the 58 patients who did not receive cranial 
irradiation achieved final heights coincident with those of the U.S. population.  
In other words, this study found cranial irradiation to be significantly associated 
with short stature in adults, but that their sample treated with chemotherapy 
alone did not exhibit any long-term deficit. 
 “Obesity and short stature are commonly observed late effects of therapy 
for childhood acute lymphoblastic leukemia” (Dalton et al. 2003:2953).  Dalton et 
al. evaluated the long-term effects of ALL treatment on height and weight for 
618 children treated between 1987 and 1995 (2003).  Three treatment groups were 
studied:  intrathecal therapy alone, intrathecal therapy with conventional cranial 
irradiation, and intrathecal therapy with irradiation twice a day.  Height and 
weight values were recorded at diagnosis and every six months thereafter.  
Body-mass index scores (BMI) were also calculated for each patient.  Results 
showed that children younger than 13 years of age experienced a greater 
decrease in height and an increase in BMI compared with their older 
counterparts.  Cranial irradiation was not shown to be an influencing factor.  An 
increased chemotherapeutic intensity, as well as younger age, was significant 
risk factors for greater growth retardation.  No statistically significant difference 
was seen in final heights between the irradiated groups and those who received 
no irradiation.  Dalton et al. found that final height was compromised in ALL 
patients and further contributed to a relative increase in weight.  They proposed 
 rather that as “patients became overweight for height; this seemed to be a result 
of relative height loss with normal weight gain rather than accelerated weight 
gain.”  Additionally Dalton et al. (2003) suggested that subsequent weight gain 
could be due to corticosteroid therapy, as was suggested by Van-Dongen-
Melman et al. (1995). 
 
Precocious Puberty 
 As treatment of childhood acute lymphoblastic leukemia is now largely 
curing with the majority of children surviving into adulthood, there has been an 
increasing concern regarding the effects of therapy on reproductive potential 
and gonadal function in these children.  Precocious or premature puberty, 
defined as “pubertal development beginning more than 2 SD before the mean 
age of the onset of puberty in the community,” has been reported after acute 
lymphoblastic leukemia (Quigley et al.  1989:143).   Pubertal development 
commencing before 9 years of age in girls and 10 years of age in boys may be 
considered precocious (Quigley et al. 1989).   
 Quigley et al. examined pubertal status and plasma levels of various 
hormones in 45 children (20 girls and 25 boys) who had received combination 
chemotherapy with 24 cGy of irradiation to the cranium.  Hormonal levels of sex 
steroids, as well as gonadotropin and inhibin, were assessed.  Germ-cell damage 
(specified by increased plasma levels of follicle-stimulating hormone) was 
 apparent in both sexes.  These findings were confirmed in the boys by the 
“absence of germ cells in the testicular biopsy specimens and by the small size of 
the testes for pubic-hair stage” (Quigley et al. 1989).  Furthermore, plasma 
inhibin levels were measurable in only 44 percent of the pubertal girls, as 
compared with over 93 percent of normal pubertal girls.  Despite evidence of 
apparent gonadal damage, the girls had an early menarche at a mean age of 
11.95 (sd = 0.91) years, as compared with the Australian standard of 12.98 (sd = 
1.11) years.   Quigley et al. (1989) concluded that treatment for ALL may 
contribute to gonadal damage in both sexes; however, puberty will occur at a 
normal age or earlier in girls.  Similarly, Greulich and Pyle (1959:8) stated that 
“in precocious puberty, the gonadal and related hormones are present 
abnormally early in quantities sufficient to cause the epiphyses of the various 
long bones to fuse before growth has continued long enough to permit the 
attainment of full normal adult stature.” 
 Brauner et al. (1984) remarked that gonadotropin deficiency can occur and 
prevent or disturb pubertal development.  Brauner et al. evaluated 29 children 
with medulloblastoma (n = 14), head and neck tumors (n = 10), or acute 
lymphoblastic leukemia (n = 5) who had received cranial irradiation before 
seven years of age.  These children were followed until the normal age of 
puberty.  Six children (5 girls and 1 boy) had precocious puberty, with puberty 
beginning two months to 2.6 years after irradiation in the girls and after seven 
 years in the boy.  One of these six children was a female who had been treated 
for ALL.  Her therapy began at six years of age with a cranial irradiation dose of 
2,400 Rad.  Precocious puberty commenced at 7.5 years of age.  Additionally, the 
child exhibited a relative growth hormone deficiency.  None of the patients 
examined had invasive hypothalmic lesions, hydrocephalus, or increased 
intracranial pressure.  Therefore, it was concluded that the precocious puberty 
can be considered a consequence of cranial (and hypothalamic and pituitary) 
irradiation (Brauner et al. 1984). 
 
Treatment Influences on Bone Mass 
 ALL patients often experience impaired GH secretion following treatment 
with cranial irradiation.  This GH decrease has been associated with a reduced 
bone mineral content.  Similarly, long-term corticosteroid and methotrexate 
therapy has also been linked to reduced bone mass.  Nysom et al. (2001) studied 
bone mass in 95 patients in first remission of ALL.   Mean whole-body bone 
mineral content (BMC) and bone mineral density area (BMDA), both useful 
variables to predict the risk of fracture, were both decreased significantly 
posttreatment.  “Reduced bone mass several years after childhood ALL appears 
to be caused by both reduced bone size and reduced size-adjusted bone mass” 
(Nysom et al. 1998:3757). 
  Regarding bone mass after childhood ALL, Atkinson et al. (1989) found 
reduced BMDA  in the radius of 16 children 8 months after completion of 
treatment.  The leukemia process was implicated as the underlying cause of 
reduced bone mass.   The study later reported that bone mass was not 
significantly reduced at the diagnosis of childhood ALL (Atkinson et al. 1990). 
 Vertebral fractures and osteoporosis may well occur in children with 
newly diagnosed ALL (Newman et al. 1973; Samuda et al. 1987).  In the past, 
these injuries were the result of infiltration and extension of leukemic tissues; 
however, they could also be an indirect result from a product of the malignant 
cells.  Prostaglandin E, ectopic parathyroid hormone, and osteoblast inhibiting 
factor have been associated with the pathogenesis of bone loss (Newman et al. 
1973; Samuda et al. 1987).   
 Gilsanz et al. (1990) also researched potential cases of osteoporosis in 42 
patients treated for childhood ALL.  The study utilized “quantitative computed 
tomography, a technique that accurately measures trabecular vertebral bone 
density, to establish or exclude the presence of osteoporosis in pediatric 
patients” (Gilsanz et al. 1990:238).  Patients who had received cranial irradiation 
had significantly lower bone density than did untreated children in the normal 
population.  Thus, the authors concluded that overall loss of bone density did 
not result from the disease or chemotherapy, but rather from the cranial 
irradiation (Gilsanz 1990). 
 Chapter Overview 
 This Review of the Literature provides an overview of Acute 
Lymphoblastic leukemia, including its numerous symptoms and treatments.  
Effort was made to mention iatrogenic effects of such anti-neoplastic therapies, 
as well as identifying radiographic methods to evaluate such harmful effects. 
 Acute Lymphoblastic Leukemia (ALL) represents the most common 
malignancy of childhood, comprising approximately 31 percent of all childhood 
malignancies (Niemeyer and Sallan 1998; Berg et al. 2000).  Each year in the 
United States, around 2,000 to 2,500 new cases are diagnosed, with ALL 
predominately striking children between the ages of two and ten years 
(Niemeyer and Sallan 1998; Berg et al. 2000). 
 ALL attacks the immune system by invading the blood and bone marrow; 
however, metastasis is often seen in extramedullary sites such as the central 
nervous system, lymph nodes, and spleen.   Symptoms of ALL commonly 
include anemia with inherent weakness and debility and joint pain, as well as 
specific oral manifestations such as swollen and bleeding gums, as well as 
periodontal infections. 
 Anti-neoplastic therapies often fail to differentiate between metabolically 
active and neoplastic cells.  Consequently, treatment effects may often harm 
healthy tissues iatrogenically.  Oral manifestations may include overretention of 
 primary teeth and delayed eruption of permanent teeth, as well as rampant 
decay, microdontia, and root stunting.   
 Numerous methods have been reviewed by which an individual’s 
skeletal growth and bone age may be assessed.  Bone age, in contrast to an 
individual’s chronological age, may properly reflect skeletal growth and 
development.  Due to reasonable accessibility and the availability of numerous 
bones for evaluating maturity, hand-wrist radiographs are commonly used in 
the evaluation of bone age.  Hand-wrist radiograph analyses were proposed by 
Greulich and Pyle in 1952, Tanner in 1975, and Fishman in 1982. 
 Treatment for ALL may also affect an individual’s overall growth and 
development.  Cranial irradiation had been shown to affect stature and weight; 
height or stature is retarded, while weight centiles typically increase.  
Individuals may also experience precocious puberty, or early-onset puberty 
(defined as commencing at least two years before the mean onset of puberty in 
the general population).  Finally, treatment for ALL most often impairs growth 
hormone secretion.  Consequently, children often experience reduced bone mass 
as well as fractures related to osteoporosis. 
 
 
 
 
 CHAPTER III 
 
MATERIALS AND METHODS 
 
 Patient records were provided by St. Jude Children’s Research Hospital in 
Memphis, Tennessee.  Institutional Review Board (IRB) approval was granted 
through both the University of Tennessee Health Science Center and St. Jude 
Children’s Research Hospital (XPD04-022).  Cases were selected based on a 
diagnosis of acute lymphoblastic leukemia.   
 The data manager at St. Jude supplied a list of patients meeting a number 
of predetermined criteria.  The following data for each patient were entered into 
an Excel spreadsheet:  date of birth, diagnosis date, sex, initial examination date, 
treatment protocols in addition to dates, and GP2 bone ages for all available 
hand-wrist films.  From these data, the following information was derived:  
chronological ages, hand-wrist bone ages, and relative tempo of growth (as 
delayed, normal or advanced).  Overall demographics for the sample were as 
follows: 
(1) All subjects had an initial diagnosis of acute lymphoblastic leukemia   
(ALL). 
(2) This cohort of children was born no earlier than 1980 and no later than 
2000. 
 (3) Subjects had an ALL diagnosis date no earlier than 1985 and no later than 
2003. 
(4) All subjects had at least one hand-wrist radiograph. 
(5) All subjects had a chronological age no older than 12 years old at initial 
diagnosis. 
We chose not to eliminate patients based on nationality.  Our sample 
represents a multicultural analysis of bone age in children with ALL.  Children 
in our study had been brought to St. Jude from throughout the United States and 
various foreign countries.  The majority of these children were white children of 
European extraction. 
Subjects were treated according to one of two protocols, either exclusive 
chemotherapy or chemotherapy combined with cranial radiation. 
 
Sample Characteristics 
ALL is a disease that characteristically strikes young children as shown in 
Figure 16.  This graph plots the age distribution of the patients studied here, by 
sex, and the median age at diagnosis is around four years of age for both sexes. 
 There were 73 children in this study (39 boys, 34 girls), each 
represented by at least on hand-wrist film.  The number of films per child was 
highly skewed, though, since most films were taken soon after the diagnosis of 
ALL (and, thus, close to the onset of treatment).  Of these 73 children, 53 had just  
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Fig. 16. Age-sequenced distributions of the children used in
the present study.  Each dot is a different individual.
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 one hand-wrist film, 10 had two films, 5 had three films, and 5 had four films.  
The total number of HW films was 108. 
Mean chronological age at diagnosis was 4.54 years (sd = 2.81), with a 
range of 0.10 up to 11.02 years of age.  Age at diagnosis did not differ between 
girls and boys (P = 0.15 by t-test). 
  
 Collection of Hand-Wrist Bone Ages 
The focus of the bone age analysis centered on determining whether the 
tempo of growth in the patients with ALL was retarded based on treatment with 
chemotherapy and/or radiation.  Bone ages were collected for each of the 73 
patients based on Greulich and Pyle’s 1959 standards (GP2).  All of the patients’ 
bone ages were assessed according to the GP2 atlas method, not the bone-specific 
method.  We necessarily assumed that the GP2 standards were appropriate for 
our sample of predominately Caucasian children.   
Bone ages were entered as decimal ages into a Microsoft Excel 
spreadsheet (Microsoft Corporation version 11.2).  For example, a patient would 
be entered with a bone age of 11.5 years, but also a bone age of 138 months.  
Similarly, patients’ chronological ages were also calculated in decimal ages. 
Data collected in the Excel file were imported into the JMP 5.0.2 statistical 
package (SAS Institute, Cary, NC).  Following exploratory data analysis and 
verifying extreme values, routine descriptive statistics were calculated, with the 
 tempo of growth (BA-minus-CA) being the key measure.  This is a mixed 
longitudinal study, but most of the data are tightly clustered near the onset of 
treatment.  Consequently, while we made as much use as possible of the more 
informative repeated measures format of some of the data (with pairing design 
tests and model II ANOVA) sample sizes were critically small.  More power was 
obtained from treating the data cross-sectionally, in which cases factorial 
ANOVA models were used.  Methods are described in Rosner (2000).  All of the 
tests were evaluated as two-tail at the conventional alpha level of 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER IV 
 
RESULTS 
 
 
 The purpose in this section was to test whether the treatment for ALL 
(chemotherapy and/or irradiation) significantly altered bone age.  Specifically, 
bone age (BA) was evaluated for each child in this study using the Greulich-Pyle 
sex-specific standards from their second edition (Greulich and Pyle, 1959), 
commonly abbreviated as GP2.  The central question was whether BA was 
depressed relative to chronological age (CA) as treatment progressed. 
 Our expectation was that the treatment of children with ALL using very 
potent drugs (with or without irradiation) would depress their tempos of 
growth, at least transiently.  The hypothesized scenario is sketched in Figure 17.  
Because of the rapid onset of ALL, we expected that bone age at diagnosis would 
not have had an opportunity to become delayed relative to CA.  Our supposition 
was that the sample of children would have bone ages equivalent to their CA 
because:  (A) we supposed that children who subsequently contract ALL are 
growing normally, as a group, and (B) similarly, ALL is an acute-onset disease 
that is not known to affect BA prior to onset.  Also, we supposed that the GP2 
sex-specific bone standards (Greulich and Pyle 1959)—which are the only 
standards available (excepting those of the Tanner et al. 1975) are appropriate to  
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Fig. 17. Diagrammatic sketch of the author’s hypothesized relationships
between CA and BA in children with ALL. The horizontal axis is chronological
age, the vertical axis is bone age, and the origin is the onset of treatment for
ALL. During phase “A,”soon after diagnosis, BA should be coincident with
CA.  We supposed that treatment would depress BA during phase “B,” but
that there would be a recovery (compensatory) phase (”C”) after the
completion of treatment.
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 this geographically heterogeneous sample of children with ALL.  (Since we did 
not have access to the HW radiographs, it was not possible to evaluate the GP2 
bone-specific standards or the TWII standards). 
 As sketched in Figure 17, we anticipated that BA would be equivalent to 
CA at the start of treatment within statistical limits.  Specifically, we tested 
whether BA-CA differed statistically from zero.  In fact, it is different.  At 
diagnosis (we selected those HW BA readings taken within 1.0 year of 
diagnosis), BA is significantly delayed, at least in boys.   There are no HW films 
prior to the onset of ALL, so we used those radiographs taken soon after the 
onset of ALL as being representative of these children’s baseline status.  For  
girls, there was a sample of only 7 which yielded a test statistic of 0.1 and an 
associated P-value of 0.95 (two-tail).  The average difference between BA and CA 
was 0.03 years (sd = 1.14).  In boys, with a more informative sample size of 12, 
the t-test was 3.2 with an associated P-value of 0.0081 (two-tail).  The average 
difference between BA and CA for these 12 boys was -0.71 (sd = 0.77) years.  
Half of the boys (6/12) had bone ages equal to or greater than the CA, but those 
with negative BA-CA differences ranged up to -2 years, and 4 boys had 
differences between -1 and -2 years, so the distribution clearly was centered 
below zero.  Since the mean CA for these 12 boys averaged only 7.00 years, the 
mean BA-CA of -0.71 suggests a 10% delay. 
  There are at least two interpretations of these results.  One is that ALL 
differentially selects children—at least boys—who are developmentally delayed.  
As will be seen, this seems unlikely.  Moreover, it disagrees with prior findings.  
A second interpretation is that the GP2 standards—derived from Midwestern 
children primarily from the 1940s—are inappropriate for these children with 
ALL because the tempos of growth and progress towards maturation occur at 
different (and probably differing) rates. 
 We supposed that the combination of antimitotic drugs used to treat ALL 
(phase “B” in Fig. 17) would discernibly depress the childrens’ tempos of 
growth, so that BA-minus-CA would become negative (and become larger 
during the course of treatment).  In fact, though, there is no evidence of this.  
There are several ways to tackle this issue statistically; we chose (1) to group the 
HW bone ages into time intervals using age at diagnosis as “time zero” and then 
(2) use one-way ANOVA to test for any difference across these intervals.  We 
were not able to get information on when treatment ceased, so these age 
intervals span all ages up to a “catch-all” interval of “over 8 years” after 
diagnosis.  HW films were not taken at any fixed interval, and the number of 
films varied appreciably among patients.  The great majority of cases had only 
one film, though, so we treated these mixed longitudinal data as if they were 
cross-sectional.  Analysis was performed separately for boys and girls since it 
seemed likely that the tempos of how the GP2 standards relate the childrens’ 
 patterns of HW maturation are at least sex-specific.  The results for the subset of 
boys are shown in Figure 18.  Visually, it is apparent from this graph that 
treatment produced no obvious drop in bone age relative to CA.   
 In Figure 18, the diamond-shaped figure at each time interval defines the 
95% confidence limits of the mean, and the middle line in the diamond is the 
mean.  The grand mean is shown as the light horizontal line across the graph.  It 
is evident that (1) the diamonds all overlap the grand mean and (2) all of the  
groups’ means are close to the grand mean.  Consequently, there is no visual 
suggestion that the value of BA-CA exhibits any trend across time. 
 For the girls, indeed, there was a transient rise in the BA-CA values (Fig. 
19, between about 0.5 and 2.0 years after diagnosis).  This doubtlessly is due to 
the predominantly cross-sectional nature of the data since it can hardly be 
supposed that treatment is “protective” of bone age. 
 These visual impressions of “no change” are supported statistically.  For 
the ANOVA of the females, the df were 9 and 35, F = 0.90 and the P-value was 
0.5314.  For the males, the df were 9 and 53, with F = 0.35 and the P-value was 
0.9519.  In this set of data, then, there is no suggestion that the chemotherapeutic 
treatment of ALL (with or without irradiation) affected the rate of progression of 
HW bone morphologies toward maturity.  We had also anticipated that, 
following treatment, the children would experience a phase of catch-up growth 
(e.g., Caruso-Nicoletti et al. 1993).  The depiction of this idea is sketched in  
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Fig. 18. Graphical results of examining BA-CA when the data are partitioned
into intervals of time into treatment (data for boys alone). By analysis of
variance, there was no significant difference among the 10 groups. Visually,
there is no trend across time; the distributions neither increase nor decrease
in the face of the serious stressors of chemotherapy.
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Fig. 19. Graphical results of examining BA-CA when the data are partitioned
into intervals of time into treatment (data for girls alone). By analysis of
variance, there was no significant difference among the 10 groups. Visually,
there is no trend across time; the distributions neither increase nor decrease
in the face of the serious stressors of chemotherapy.
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 phase “C” of Figure 17.  In fact, though, since there was no depression of the rate 
of maturation during treatment, there would be no need for a compensatory 
phase.  
 To confirm this, we tested the two “ends” of the data.  Specifically, we 
tested whether the differences in BA minus CA at the start of treatment (within 
1.0 year of diagnosis) was different from that of HW ages more than 6.0 years  
after diagnosis.  (Again, we could not obtain information on when treatment 
ceased, so we used > 6.0 years after diagnosis as a conservative breakpoint.) 
 In both comparisons (for boys and for girls; Figs. 20, 21), the variability in 
BA-CA increased from pre- to posttreatment, but this is fully anticipated because 
the children had grown older and variability in this parameter increases with 
age (Garn et al. 1958, 1962).  Inferentially, there was no difference across time; 
BA-CA did not change from soon after diagnosis to several years after treatment.  
In girls, the mean of BA-CA was 0.03 years for the set of HW examinations made 
within a year of diagnosis and 0.23 years for the set of readings taken more than 
6 years after diagnosis.  With 1 and 20 df and F = 0.15, the P-value is 0.7033.  For 
the boys, the mean BA-CA was -0.71 years for the grouping of the examinations 
made within a year of diagnosis and -0.47 years for those in excess of 6.0 years 
after diagnosis.  With 1 and 21 df and F = 0.24, the P-value is 0.6262.  There is,  
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Fig. 20. Graphical results of examining BA-CA when just the data at the
two extremes of time-in-treatment are compared (data for girls alone). By
analysis of variance, there was no significant difference between the 2 groups.
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Fig. 21. Graphical results of examining BA-CA when just the data at the
two extremes of time-in-treatment are compared (data for boys alone). By
analysis of variance, there was no significant difference between the 2 groups.
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 then, no evidence that treatment for ALL had any effect on the progress of HW 
bone age towards maturity. 
 For completeness, we also investigated whether the statistical power of a 
repeated-measures design would disclose any effect of treatment on bone age.  
We culled the data set for children with at least two HW films that were taken at 
least one year apart.  Then BA-CA from the earliest film (closest to the diagnosis  
of ALL) was compared to BA-CA from the most recent film (when the child had 
been in treatment the longest).  This resulted in a sample size of 17 pairs of BAs 
(sexes combined).  There was some apparent change in the mean BA-CA with 
time, but the direction of the change was opposite what could be explained by 
treatment.  Mean BA-CA was 0.43 years at the first examination and 0.16 years at 
the most recent examination.  At face value, this change suggests that treatment 
is protective of bone age, which seems uninterpretible in light of the drugs’ 
known actions.  On the other hand, this change across time is not significant 
statistically (t = 1.95; df = 16; P = 0.0693). 
 This test would seem to be the most likely to find an effect of treatment on 
BA if one exists, and the results are negative.  Indeed, the trends are not even in 
the anticipated direction.  In sum, then, there seems to be no suggestion in the 
present data set that the tempo of growth as assessed through hand-wrist BA is at 
all affected by treatment for ALL. 
  There is a cautionary note in these results.  If one were to ignore the bone 
ages from the early films, and, say, only test whether the most recent bone ages 
were affected (i.e., those BAs from children who were longest in treatment), the 
mean BA-CA is -0.19 (n = 73), which is suggestive that treatment for ALL does 
depress the rate of maturation—though not significantly (df = 72; t = 1.54; P = 
0.1289).  The error in this assumption becomes clear when it is recognized that 
the earliest films show that BA is even more “affected” (mean = -0.39 years; t = 
2.44; P = 0.0203).   
 Our contention is that the bone age standards (GP2) produce the observed 
BA-CA discrepancies because the tempos of growth are different in the GP2 
sample versus how quickly the children with ALL in the present study were 
maturing.  Treatment for ALL has serious repercussions on the amounts of 
growth in the affected children (Kirk et al. 1987; Clayton et al. 1998; Dalton et al. 
2003), but it appears to spare the tempo of growth as measured by HW bone age. 
 
 
 
 
 
 
 
 
 
 CHAPTER V 
 
DISCUSSION 
 
 Acute Lymphoblastic Leukemia (ALL) is the most common malignancy of 
childhood, constituting approximately 31% of all childhood malignancies 
(Niemeyer and Sallan 1998; Berg et al. 2000).  While ALL accounts for nearly 75% 
of all leukemias in children, it accounts for less than 1% of all adult malignancies 
(Perkins et al. 1997; Berg et al. 2000). 
 ALL strikes children primarily between two and ten years of age, with the 
peak age between two and three years.  However, it can also attack adolescents 
and adults, with a substantial increase around 65 years of age (Berg et al. 2000).  
Current statistics from the Surveillance, Epidemiology, and End Results 
Program (SEER) reveals that the incidence of ALL in the United States increased 
from 2.7 to 3.3 cases per 100,000 children aged 0 to 14 years old during the years 
of 1973 to 1995.  Each year, around 2,000 to 2,500 new cases of ALL are diagnoses 
in the United States (Niemeyer and Sallan 1998). 
 The cause of ALL is not known, though several explanations for an 
overall cause have been explored.  Numerous environmental factors have been 
examined, including ionizing radiation, the use of drugs and chemicals, as well 
as various viruses.  Several chemical substances, such as benzene, 
 chloramphenicol, and phenylbutazone, have been linked to the disease.  
Additionally, several viruses have shown associations with leukemia.  These 
include a statistical linkage of the Epstein-Barr virus with African Burkitt’s 
lymphoma, the human T-cell leukemia-lymphoma virus I (HTLV-I) with adult 
T-cell leukemia-lymphoma (ATL), and the HTLV-II virus with atypical hairy-cell 
leukemia (Perkins et al. 1997). 
The overall prognosis of patients with ALL is promising as rates of 
remission continue to increase.  Survival rates for children are currently near 80 
percent, which demonstrate the obvious progress that has been made in the 
treatment of ALL (Pui 1999).  The current high and improving survival rates of 
ALL are due in large part to research efforts and improved treatment strategies 
(Goho 1993).  When considering the treatment course for a person with ALL, a 
number of factors must be considered:  the ALL subtype, the comparative 
success of previous treatments, levels of leukemic cells in the blood, as well as 
the patient’s age and overall health (Wells et al. 1983).  Consequently, overall 
treatment may vary substantially from person to person. 
Various options exist for the treatment of ALL, including chemotherapy, 
radiation, and bone marrow transplantation.  Physicians may use one therapy 
exclusively or combine methods to treat particular cases of ALL.  Multimodal 
therapy “creates synergistic and additive effects” not normally gained from the 
utilization of one therapy only (Goho 1993). 
 Chemotherapy is the treatment currently chosen for most types of acute 
leukemias.  Chemotherapeutic agents target DNA replication in cells and strive 
to prevent cancer cells from invading, multiplying, metastasizing, and 
destroying the host (Skeel and Khleif 2003).  While the ultimate mechanisms by 
which cancer drugs induce cell death are uncertain, the majority of efficient 
cancer agents are believed to either generate chemical lesions in DNA or 
interfere with the synthesis of DNA.  Destructive mechanisms may range from 
apoptosis (programmed cell death) to progression of cell death following mitosis 
(Chabner et al. 1999). 
While attempting to destroy cancer cells, chemotherapy often affects 
normal cells or organs that are undergoing cell reproduction at enhanced rates.  
Mucosal linings, such as those of the mouth and intestines, as well as the skin, 
hair follicles, and bone marrow, are often affected.  The overall goal of a 
chemotherapeutic agent, though, is to produce marked destruction of cancer 
cells, while providing minimal damage to normal cells of the body (e.g., Skeel 
and Khleif 2003).  Side effects of chemotherapy may include anemia, nausea, 
anaphylaxis, stomatitis, xerostomia, hair loss (alopecia), diarrhea, constipation 
and/or an altered nutritional status due to gastrointestinal tract insult (Tipton 
2003). 
The antimitotic effect and toxicity of the drugs used in the treatment of 
ALL are quite apparent from the literature.  Therefore, our hypothesis was that 
 although a person’s overall growth may not be affected by such agents, his/her 
tempo of growth could be affected significantly.  Adult and adolescent stature 
has been shown to be greatly affected by anti-neoplastic treatments, particularly 
in combination with irradiation therapy.  However, these findings reflected only 
changes in a person’s height (and often weight), not a patient’s tempo of growth 
as assessed from bone age.   In the present study, the question was whether a 
patient’s rate of maturation was influenced by such treatment. 
Tanner et al. (1975:1) stated,  
The concept of physical maturity, while familiar in 
general terms, does not suggest immediately a method by 
which it can be quantified, let alone measured.  Maturity 
differs in an important way from a measurement such as 
stature, in that the normal growth process takes every 
individual from one common condition of being wholly 
immature to another of being wholly mature.  It thus makes 
sense to measure maturity on, say, a percentage basis from 0 
to 100.  Stature lacks these common end points; a child who 
is ‘tall for his age’ may be so because he is more mature than 
his coevals, but he may simply be a tall child of average 
maturity, which will eventually be a tall adult.  Stature and 
other ‘size’ measures can thus not be used to define 
maturity, except possibly in retrospect when the adult value 
is known. 
 
A set of distinct events commonly occurring during growth are needed to 
properly define maturity.  Examples of such events would be the eruption of a 
specific tooth, or (in females) the onset of menarche.  One may then assume that 
an individual who has undergone a particular event is more mature than 
another which has not undergone the event.  Furthermore, levels of maturity can 
 be assessed from “a series of events that always occur in the same sequence from 
a single event” (Tanner et al. 1975).  Thus, in females, the sequence of breast 
development could serve to define a series of three specific events.  A female 
with fully developed breasts is more mature than a female whose breasts are 
developing, and a female whose breasts are developing is more mature than a 
female whose breasts have not yet begun to develop.  “Events of this kind are 
often referred to as developmental ‘milestones’, the name indicating the 
intention to define the distance an individual has traveled along the common 
road to full maturity” (Tanner et al. 1975:1). 
Many series of events exist by which maturation may be measured.  
Examples may include eruption of the each tooth in the primary and permanent 
dentition as well as initial presentation and ossification of the bones of the hand 
and wrist.  The difficulty in assessing maturity then becomes how to join the 
evidence from many sequences of events, many of which are often invariant 
(Tanner et al. 1975).   
The best known method of assessing maturity by using the bones of the 
hand and wrist complex was developed by Greulich and Pyle in 1959.  Their 
atlas, which presents a series of “typical” radiographs of children at some 30 
points along the maturity scale, allows the user to match a given radiograph as 
well as possible to one stage.  “The maturity recorded is then given by the age 
that characterizes the closest match” (Tanner et al. 1975).  Subjectivity of 
 measurement is obviously a disadvantage of this method; a specific radiograph 
will not, more than likely, exactly match one in the atlas series.  Furthermore, the 
issue of whether to how to measure a radiograph which falls between two in the 
atlas is not addressed.  Despite these limitations, the Greulich and Pyle method 
is used quite often to assess maturity through bone or skeletal age (Tanner et al. 
1975). 
Average bone or skeletal ages illustrate the maturation status in which 
normal children, male and female, attain an established chronological age 
(Jimenez-Castellanos et al. 1996).  Similar to the growth of organs in the human 
body, bones of the skeleton progress through their morphological development 
at different age-specific rates in time.  In the child, new (secondary) ossification 
centers appear over a span of time, and existing ones remodel their 
morphologies.  Knowing initiation times and morphological changes on bones in 
the hand and wrist provide a means of relating skeletal age, or “developmental 
age” to chronological age, which is the person’s age in calendar years. 
Hand-wrist radiographs are commonly used in the assessment of 
biological age because (1) the hand and wrist are reasonably accessible, (2) those 
vital organs particularly at risk to radiation damage are not in close proximity, 
and (3) there are numerous bones available by which developmental maturity 
may be measured.  The standards used in this study to which hand-wrist 
 radiographs were compared were formulated by Greulich and Pyle in 1959, and 
are known as the GP2 standards. 
The present study involved scoring the 108 hand-wrist films from 73 
children (39 boys, 34 girls) who were treated for acute lymphoblastic leukemia at 
St. Jude Children’s Research Hospital, Memphis, TN.  Mean chronological age at 
diagnosis was 4.54 years (sd = 2.81), with a range of 0.10 up to 11.02 years of age.  
The number of films per child was highly skewed, because most were taken 
soon after the diagnosis of ALL (and, thus, the onset of treatment).  Of these 73 
children, 53 had just one hand-wrist film.   
How large are population differences in the tempos of HW maturation?  
In other words, can we anticipate that the GP2 standards—based on Ohio 
children growing up in the 1930s and 1940s—are broadly representative of white 
childrens’ growth?  There have not been many published studies.  Mappes et al. 
(1992) found no difference in rates of HW development between contemporary 
samples of young adolescents from Ohio and Tennessee (though dental ages 
differed significantly between the same groups).  Loder et al. (1993) and Ontell et 
al. (1996) found only modest differences between blacks, whites, and Asian 
children growing up in Northern California, except that blacks showed a spurt 
in BA at adolescence.  Van Rijn et al. (2001) found the GP2 standards to be 
appropriate for contemporary Dutch children.  Mora et al. (2001) reported (A) 
that variability exceeds that of the GP2 standards and (B) that their white sample 
 from Southern California was delayed during the pubertal interval but then 
caught up with the GP2 standards. 
Fry (1968) published an insightful comparison of the two commonly used 
HW bone age atlases, name the Tanner-Whitehouse norms based on British 
children (1959) and the GP2 standards based on mid-American children from 
Cleveland, Ohio (Greulich and Pyle 1959).  Fry realized that the photographs of 
the HW bones at each stage in the GP2 atlas could be scored using the 20 bone 
RUS bone-specific method of Tanner and Whitehouse.  Fry scored the skeletal 
ages of the 25 grades for boys (with CA of 1 through 17 years of age) and the 20 
grades for girls (with CA of 1 through 15 years of age). 
Data for the boys are plotted in Figure 22, where it is evident that the TW 
sample matures significantly faster than the GP2 sample.  As shown in the top 
graph, the British children were appreciably more mature at most stages than 
the Ohio boys.  The difference between groups (bottom graph) starts off fairly 
small but by stage 10 (3 years of age), the difference is about 1 ½ to 2 years 
throughout the rest of the graph.  Use of the TW standards would, then 
substantially over-estimate the bone age of the ALL children in the present study 
and correspondingly under-estimate their amounts of potential growth ahead of 
them. 
Comparable differences are obtained for the girls (Fig. 23).  These 
comparisons show that the tempos of growth differ (A) by age (the lines are not 
Fig. 22. Comparison of the Tanner-Whitehouse and Greulich-Pyle hand-
wrist bone age standards for boys.  See text for details.
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Fig. 23. Comparison of the Tanner-Whitehouse and Greulich-Pyle
hand-wrist bone age standards for girls.  See text for details.
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 parallel even accounting for sample fluctuation) and (B) by sex. 
Viewing the extent of differences between the TW and GP2 standards 
suggest that much smaller differences between the sample of children with ALL 
and the GP2 standards in the present study are easily  attributable to population 
differences in the tempos of maturation. 
Several studies utilized stature, as opposed to bone age, to assess 
“development” of children treated for ALL.  Dalton et al. found a slight decrease 
in height in children who received cranial irradiation (2003).  This decrease, 
however, was not statistically significant when these children were compared to 
nonradiated children.  Additionally, the means for the z scores at diagnosis for 
the sample were +0.22 for height and +0.11 for weight, revealing that, on 
average, the sample was slightly taller and heavier than expected according to 
United States growth data (Dalton et al. 2003).   
Herber et al. (1985) evaluated growth in long term survivors of several 
childhood malignancies treated with cranial radiotherapy.  Cranial irradiation 
“may cause growth hormone deficiency due to disruption of the hypothalamo-
pituitary axis” (Herber et al. 1985:438).   Since treatment of malignancies is not 
tumor specific and all dividing cells are affected, “there is no reason why the 
cells at the epiphyseal plate should be spared, which raises that possibility of  
growth retardation during treatment” (Herber et al. 1985:440).  However, the 
mean of a smaller sample (5 treated with chemotherapy, 10 treated with spinal 
 irradiation, and 19 treated with cranial irradiation) was 12.12 (sd = 3.93) years as 
compared to the mean skeletal age overall at 12.02 (sd = 3.82) years.  In addition, 
bone age was retarded by no more than 18 months in any patient.  These results 
indicated that bone age was affected only slightly if at all.  The majority of 
children in the study who received cranial irradiation had been diagnosed with 
acute lymphoblastic leukemia. Additionally, previous reports have suggested 
that children diagnosed with ALL are taller than average at diagnostic 
presentation (Griffin and Wadsworth 1980; Broomhall et al. 1983).   
Kirk et al. (1987) reported high rates of diminished stature in children 
treated for ALL.  However, overall growth retardation was not shown.   Stature 
had decreased by more than one standard deviation in 32 percent of survivors at 
4 years post-diagnosis and in 71 percent at 6 years post-diagnosis.  Standard 
deviation scores were constructed as standard deviation scores from the 
population mean.  Kirk et al. (1987) also mentioned growth of younger children 
and those children especially tall for their age at diagnosis were more 
susceptible to reductions in overall stature. 
Birkebaek and Clausen (1998) evaluated height and weight patterns in 
children up to 20 years after treatment for ALL.  Their results disclosed similar 
height deviation scores at diagnosis and at follow-up; however, there was a 
significant decrease in scores during treatment.  As was similar to 
aforementioned studies, the sample of children with ALL evaluated was 
 significantly taller at the time of diagnosis when compared with the normal 
population.  “Whether the coexistence of ALL and a high growth rate is 
incidental or the result of a common factor is not known” (Birkebaek and 
Clausen 1998:163). 
Though several of the aforementioned studies noted an overall decrease 
in stature, bone age or the tempo of growth has not been shown to be adversely 
affected by chemotherapy and/or radiation.  That is, chronological age (CA) in 
children treated for ALL was essentially equal to bone age (BA).  This finding is 
optimistic in that it signifies that growth in children with ALL is not 
compromised, as one might assume.   It is important to note that a long-term or 
permanent decrease in final adult stature was not seen unless (1) the patient 
sustained irreversible damage to the hypothalamic-pituitary axis, which in turn 
adversely affected the production and release of essential growth hormones 
and/or (2)  the patient was so young that critical endocrinological changes were 
not expressed (Lawrence et al. 1971). 
Statistical analysis revealed a desirable situation.  We analyzed the data 
using analysis of variance, having partitioned the HW bone ages into intervals 
based on how long past the onset of treatment the examination was made, which 
is concomitantly, the age at diagnosis.  The data for boys (Fig. 18) showed that 
the HW films taken within one year of diagnosis exhibited a developmental 
delay (mean BA-CA of -0.71 years), but the subsequent films showed a gradual 
 diminution in the size of BA-CA such that (1) only the first age interval showed 
a significant delay in HW bone age and (2) BA-CA improved over time.  It 
seemed parsimonious to assume that the initial discrepancy (a 10% delay in BA 
compared to CA) because these children’s tempo of growth (irrespective of ALL) 
differed from the tempo of children used to develop the GP2 standards.  
Alternatively, it could be argued from these results that (1) in boys (but not in 
girls) ALL delays growth, so BA-CA is significant at the start of treatment and 
(2) the potent antimitotic drugs used to treat the disease is somehow protective 
such that BA-CA diminishes towards zero during and after treatment.  This 
interpretation flies in the face of several known iatrogenic consequences of 
chemotherapeutic treatment, and this interpretation is not supported by the few 
other studies of HW bone age in children treated for ALL (Tamminga et al. 1993). 
Moreover, the girls in the present sample show a simpler pattern (Fig. 19).  
Mean BA-CA is very close to zero at the start of treatment and remains there — 
there is no statistical evidence that treatment has any effect on BA-CA. 
These data can be expressed in another fashion to affirm these earlier 
tests.  Here we forego the categorization of cases into intervals after diagnosis 
and simply plot BA-CA against time in treatment (Fig. 24).  The linear regression 
lines, calculated by sex, both begin slightly below zero but have positive slopes.  
For boys, the Y intercept, which is the status at diagnosis, shows that BA-CA 
starts off negative (intercept = -0.66; t = 3.3; P = 0.0018), but BA-CA diminishes 
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 insignificantly with time (b = +0.05; t = 1.0; P = 0.3062). 
For girls, there is no evidence of the initial depression in BA seen for boys; 
the Y intercept is -0.08, which is not significantly different from zero (t = 0.3; P = 
0.7979).  The slope of the line fit to the data for girls is statistically 
indistinguishable from a horizontal line, meaning that there is no delay at 
diagnosis, nor does treatment have any discernible effect on the tempo of HW 
bone maturation.  In sum, these results wholly duplicate those describe before, 
but use a different method of assessment to confirm the results. 
It is simpler to invoke sampling fluctuation (i.e., a nonrepresentative 
sampling of boys early in treatment) to explain the observed BA-CA depression 
and/or a different tempo of growth in the GP2 standards than to accept that BA-
CA depression is biologically important.  These conjectures can be solved with 
replication of this study using different children who have been treated for ALL. 
   
 
 
 
 
 
 
 
 
 CHAPTER VI 
 
SUMMARY AND CONCLUSIONS 
 
 Acute Lymphoblastic Leukemia (ALL) constitutes the most common 
malignancy of childhood, consisting of 31 percent of all childhood malignancies.  
ALL primarily strikes children between primarily two and ten years of age, but 
may occur in adolescents and adults.  Treatment strategies to target the disease 
include individual or combination therapy with chemotherapeutic agents, 
irradiation of the neck and/or spine, and, occasionally, bone marrow 
transplantation.   The aggressive nature of anti-neoplastic therapies often results 
in numerous craniofacial and dental sequelae as well as additional iatrogenic 
effects on the entire body.  Cranial irradiation may adversely affect the 
hypothalamic-pituitary axis, resulting in a decrease in growth hormone 
production.  Children with ALL may experience a transient reduction in stature 
coincident with therapy, and the risk of permanent size diminution increases 
greatly if treatment includes cranial irradiation. 
 The present study used hand-wrist radiographs to determine the 
maturational status of children treated for ALL.  We anticipated that anti-
neoplastic therapies would influence a child’s bone development and thus 
children in our sample would show delayed bone development. 
  Hand-wrist (HW) radiographs of 73 children (39 boys, 34 girls) treated at 
St. Jude Children’s Research Hospital for ALL were evaluated to assess HW 
bone age.  Mean chronological age at diagnosis was 4.54 years (sd = 2.81). Bone 
ages were scored using Greulich and Pyle’s 1959 atlas method.      
 We supposed that the combination of antimitotic drugs used to treat ALL 
would discernibly depress the childrens’ tempos of growth, so that BA-CA (bone 
age minus chronological age) would be negative.  Instead, the data showed no 
evidence of any effect.  In fact, since there was no depression of the rate of 
maturation during treatment, there was no need for a compensatory, or “catch-
up,” phase.  There is no evidence in this study that treatment for ALL has any 
effect on the progress of hand-wrist morphological bone age.  Treatment for ALL 
spares the tempo of growth as assessed by HW bone age.   
 This finding is quite favorable from the standpoint of the child’s overall 
health, as well as for orthodontic treatment.  Orthodontics frequently harnesses a 
child’s growth potential or “growth spurt” to improve the treatment outcome.  
Certain Class II or Class III malocclusions may be corrected in young children 
through orthodontic techniques that maximize the child’s growth potential.  
Such examples might include treating a Class II malocclusion with a facebow 
headgear to the maxillary molars.  The headgear serves to constrain the maxilla, 
while allowing the mandible to grow forward.  Knowing that the growth 
potential of children treated for ALL is not hindered or delayed ensures these 
 children may be treated orthodontically as normal individuals with normal 
growth spurts.  Orthodontic treatment in these children, however, must always 
be in cooperation with and under the approval of the supervising oncologist or 
physician.  Communication between the oncologist, dentist and orthodontist, as 
well as any additional physicians, may guarantee that the child’s overall health 
is best managed. 
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 the 73 children with ALL in this study  
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Fig. A-1. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1056).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-2. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1036).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-3. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1020).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-4. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1039).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-5. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1029).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-6. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1059).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-7. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1003).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-8. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1030).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-9. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1007).  The square symbol denotes age at
diagnosis of ALL.
BJ
J
0
2
4
6
8
10
12
14
0 2 4 6 8 10 12 14
Bo
ne
 A
ge
Chronological Age
Fig. A-10. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1052).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-11. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1024).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-12. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1047).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-13. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1010).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-14. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1025).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-15. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1032).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-16. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1013).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-17. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1038).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-18. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1040).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-19. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1018).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-20. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1055).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-21. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1033).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-22. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1065).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-23. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1008).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-24. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1058).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-25. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1071).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-26. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1041).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-27. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1066).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-28. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1012).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-29. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1045).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-30. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1063).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-31. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1019).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-32. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1022).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-33. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1068).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-34. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1061).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-35. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1017).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-36. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1043).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-37. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1062).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-38. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1054).  The square symbol denotes age at
diagnosis of ALL.
B J
J J
J
0
2
4
6
8
10
12
14
0 2 4 6 8 10 12 14
Bo
ne
 A
ge
Chronological Age
Fig. A-39. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1051).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-40. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1031).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-41. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1034).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-42. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1069).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-43. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1027).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-44. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1006).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-45. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1023).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-46. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1057).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-47. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1072).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-48. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1028).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-49. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1009).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-50. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1064).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-51. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1015).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-52. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1050).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-53. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1001).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-54. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1021).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-55. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1011).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-56. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1067).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-57. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1000).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-58. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1016).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-59. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1004).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-60. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1026).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-61. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1048).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-62. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1042).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-63. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1049).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-64. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1044).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-65. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1014).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-66. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1046).  The square symbol denotes age at
diagnosis of ALL.
BJ
J
0
2
4
6
8
10
12
14
0 2 4 6 8 10 12 14
Bo
ne
 A
ge
Chronological Age
Fig. A-67. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1060).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-68. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1070).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-69. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1002).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-70. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1053).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-71. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1037).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-72. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1005).  The square symbol denotes age at
diagnosis of ALL.
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Fig. A-73. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1035).  The square symbol denotes age at
diagnosis of ALL.
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 Mary Elizabeth Martin was born in Norfolk, Virginia, on August 
15, 1977 where her father, John Martin, was stationed with the United 
States Navy.  Her family moved to Middle Tennessee when she was six 
months old and resided briefly with her paternal grandparents in 
Springfield, Tennessee.  Her family eventually settled in Hendersonville, 
Tennessee where she graduated from Hendersonville High School in May 
of 1995.  Mary Beth attended The University of Tennessee at Knoxville 
where she majored in Biology and received a Bachelor of Science degree in 
May of 1999.  She received her dental training and a Doctor of Dental 
Surgery degree from The University of Tennessee at Memphis in May of 
2003.  In August of 2003, she entered The University of Tennessee’s 
Orthodontic program.  She is expected to receive a Master of Dental 
Science degree in May 2006.  Following graduation, Mary Beth will join 
her husband, David, to live in Jonesboro, Arkansas.  
